UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q



(Mark One)
x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April ~~2, 2017~~1, 2018



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number 1-5353

TELEFLEX INCORPORATED

(Exact name of registrant as specified in its charter)



Delaware		23-1147939
(State or other jurisdiction of incorporation or organization)		(I.R.S. employer identification no.)



550 E. Swedesford Rd., Suite 400, Wayne, PA		19087
(Address of principal executive offices)		(Zip Code)

(610) 225-6800

(Registrant’s telephone number, including area code)

(None)

(Former Name, Former Address and Former Fiscal Year,

If Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.



Large accelerated filer	x		Accelerated filer	¨

Non-accelerated filer	¨	(Do not check if a smaller reporting company)	Smaller reporting company	¨

			Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The registrant had ~~44,981,275~~45,543,546 shares of common stock, par value $1.00 per share, outstanding as of ~~May 1, 2017.~~April 30, 2018.

TELEFLEX INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED APRIL ~~2, 2017~~1, 2018

TABLE OF CONTENTS



		Page
PART I — FINANCIAL INFORMATION

Item 1:	Financial Statements (Unaudited):	2
	Condensed Consolidated Statements of Income	2
	Condensed Consolidated Statements of Comprehensive Income	3
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Cash Flows	5
	Condensed Consolidated Statements of Changes in Equity	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3229
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	4138
Item 4:	Controls and Procedures	4138

PART II — OTHER INFORMATION

Item 1:	Legal Proceedings	4240
Item 1A:	Risk Factors	4240
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	4240
Item 3:	Defaults Upon Senior Securities	4240
Item 4:	Mine Safety Disclosures	4240
Item 5:	Other Information	4240
Item 6:	Exhibits	4341

SIGNATURES		4442

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars and shares in thousands, except per share)						(Dollars and shares in thousands, except per share)
Net revenues	$	487,881		$	424,893		$	587,230		$	487,881
Cost of goods sold	232,321			199,746			255,960			232,321
Gross profit	255,560			225,147			331,270			255,560
Selling, general and administrative expenses	163,969			136,348			215,337			163,969
Research and development expenses	17,827			12,353			26,027			17,827
Restructuring charges	12,945			9,968			3,063			12,945
Gain on sale of assets	—			(1,019		)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	60,819			67,497			86,843			60,819
Interest expense	17,726			13,784			25,943			17,726
Interest income	(169		)	(80		)	(273		)	(169		)
Loss on extinguishment of debt	5,582			—			—			5,582
Income from continuing operations before taxes	37,680			53,793			61,173			37,680
(Benefit) taxes on income from continuing operations	(2,669		)	2,613
Taxes (benefit) on income from continuing operations							6,242			(2,669		)
Income from continuing operations	40,349			51,180			54,931			40,349
Operating loss from discontinued operations	(282		)	(382		)
Benefit on loss from discontinued operations	(103		)	(70		)
Loss from discontinued operations	(179		)	(312		)
Operating income (loss) from discontinued operations							1,235			(282		)
Tax benefit on income (loss) from discontinued operations							(18		)	(103		)
Income (loss) from discontinued operations							1,253			(179		)
Net income	40,170			50,868			$	56,184		$	40,170
Less: Income from continuing operations attributable to noncontrolling interest	—			179
Net income attributable to common shareholders	$	40,170		$	50,689
Earnings per share available to common shareholders:
Earnings per share:
Basic:
Income from continuing operations	$	0.90		$	1.22		$	1.21		$	0.90
Income (loss) from discontinued operations	(0.01		)	—			0.03			(0.01		)
Net income	$	0.89		$	1.22		$	1.24		$	0.89
Diluted:
Income from continuing operations	$	0.87		$	1.05		$	1.18		$	0.87
Loss from discontinued operations	(0.01		)	(0.01		)
Income (loss) from discontinued operations							0.02			(0.01		)
Net income	$	0.86		$	1.04		$	1.20		$	0.86
Dividends per share	$	0.34		$	0.34		$	0.34		$	0.34
Weighted average common shares outstanding
Basic	44,893			41,647			45,329			44,893
Diluted	46,615			48,782			46,695			46,615
Amounts attributable to common shareholders:
Income from continuing operations, net of tax	$	40,349		$	51,001
Income (loss) from discontinued operations, net of tax	(179		)	(312		)
Net income	$	40,170		$	50,689

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

Three Months Ended
April 2, 2017 March 27, 2016
(Dollars in thousands)
Net income $ 40,170
$ 50,868
Other comprehensive income, net of tax:
Foreign currency translation, net of tax of $(7,089) and $(4,177) 46,982
20,455
Pension and other postretirement benefit plans adjustment, net of tax of $(532) and $(629) 890
1,238
Derivatives qualifying as hedges, net of tax of $(555) and $(379) 1,728
1,480
Other comprehensive income, net of tax: 49,600
23,173
Comprehensive income 89,770
74,041
Less: comprehensive income attributable to noncontrolling interest —
158
Comprehensive income attributable to common shareholders $ 89,770
$ 73,883



	Three Months Ended
	April 1, 2018		April 2, 2017
	(Dollars in thousands)
Net income	$	56,184	$	40,170
Other comprehensive income, net of tax:
Foreign currency translation, net of tax of $(5,872) and $(7,089)	81,188		46,982
Pension and other postretirement benefit plans adjustment, net of tax of $(234) and $(532)	881		890
Derivatives qualifying as hedges, net of tax of $(211) and $(555)	621		1,728
Other comprehensive income, net of tax:	82,690		49,600
Comprehensive income	$	138,874	$	89,770

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	April 2, 2017		December 31, 2016		April 1, 2018		December 31, 2017
	(Dollars in thousands)				(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	689,129	$	543,789	$	378,872	$	333,558
Accounts receivable, net	282,872		271,993		359,140		345,875
Inventories, net	355,289		316,171		403,676		395,744
Prepaid expenses and other current assets	47,238		40,382		52,998		47,882
Prepaid taxes	20,599		8,179		7,234		5,748
Assets held for sale	—		2,879		3,239		—
Total current assets	1,395,127		1,183,393		1,205,159		1,128,807
Property, plant and equipment, net	355,234		302,899		389,519		382,999
Goodwill	1,815,498		1,276,720		2,264,447		2,235,592
Intangible assets, net	1,620,454		1,091,663		2,390,555		2,383,748
Deferred tax assets	1,963		1,712		3,969		3,810
Other assets	44,160		34,826		46,951		46,536
Total assets	$	5,232,436	$	3,891,213	$	6,300,600	$	6,181,492
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	131,095	$	183,071	$	77,500	$	86,625
Accounts payable	82,018		69,400		84,686		92,027
Accrued expenses	82,390		65,149		101,128		96,853
Current portion of contingent consideration	669		587		162,061		74,224
Payroll and benefit-related liabilities	65,927		82,679		80,418		107,415
Accrued interest	12,686		10,450		20,503		6,165
Income taxes payable	8,043		7,908		13,500		11,514
Other current liabilities	9,530		8,402		11,978		9,053
Total current liabilities	392,358		427,646		551,774		483,876
Long-term borrowings	1,957,797		850,252		2,154,217		2,162,927
Deferred tax liabilities	460,654		271,377		616,711		603,676
Pension and postretirement benefit liabilities	130,226		133,062		117,874		121,410
Noncurrent liability for uncertain tax positions	17,939		17,520		12,628		12,296
Noncurrent contingent consideration					119,796		197,912
Other liabilities	54,558		52,015		167,100		168,864
Total liabilities	3,013,532		1,751,872		3,740,100		3,750,961
Commitments and contingencies
Convertible notes - redeemable equity component	—		1,824
Mezzanine equity	—		1,824
Total shareholders' equity	2,218,904		2,137,517		2,560,500		2,430,531
Total liabilities and shareholders' equity	$	5,232,436	$	3,891,213	$	6,300,600	$	6,181,492

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars in thousands)						(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net income	$	40,170		$	50,868		$	56,184		$	40,170
Adjustments to reconcile net income to net cash provided by operating activities:
Loss (income) from discontinued operations	179			312
(Income) loss from discontinued operations							(1,253		)	179
Depreciation expense	14,180			12,602			14,832			14,180
Amortization expense of intangible assets	18,785			15,357			37,816			18,785
Amortization expense of deferred financing costs and debt discount	1,406			4,377			1,178			1,406
Loss on extinguishment of debt	5,582			—			—			5,582
Gain on sale of assets	—			(1,019		)
Fair value step up of acquired inventory sold	7,832			—			—			7,832
Changes in contingent consideration	179			377			9,592			179
Stock-based compensation	4,240			3,437			4,787			4,240
Deferred income taxes, net	(3,081		)	756			(1,472		)	(3,081		)
Other	(2,703		)	(3,114		)	(1,272		)	(2,703		)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	18,691			(10,568		)	(3,402		)	18,691
Inventories	(5,322		)	(5,104		)	32			(5,322		)
Prepaid expenses and other current assets	(1,224		)	(3,749		)	(3,406		)	(1,224		)
Accounts payable and accrued expenses	2,696			4,502			(27,185		)	2,696
Income taxes receivable and payable, net	(10,670		)	(2,202		)	417			(10,670		)
Net cash provided by operating activities from continuing operations	90,940			66,832			86,848			90,940
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(12,894		)	(7,822		)	(15,747		)	(12,894		)
Proceeds from sale of assets	6,332			1,251			—			6,332
Payments for businesses and intangibles acquired, net of cash acquired	(975,524		)	—			(3,684		)	(975,524		)
Net cash used in investing activities from continuing operations	(982,086		)	(6,571		)	(19,431		)	(982,086		)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500			—			—			1,194,500
Reduction in borrowings	(138,251		)	(9		)	(18,500		)	(138,251		)
Debt extinguishment, issuance and amendment fees	(19,114		)	—			(74		)	(19,114		)
Net proceeds from share based compensation plans and the related tax impacts	(505		)	3,180			1,400			(505		)
Payments for contingent consideration	(79		)	(61		)	(91		)	(79		)
Dividends paid	(15,287		)	(14,179		)	(15,447		)	(15,287		)
Net cash provided by (used in) financing activities from continuing operations	1,021,264			(11,069		)	(32,712		)	1,021,264
Cash flows from discontinued operations:
Net cash used in operating activities	(266		)	(126		)	(206		)	(266		)
Net cash used in discontinued operations	(266		)	(126		)	(206		)	(266		)
Effect of exchange rate changes on cash and cash equivalents	15,488			5,126			10,815			15,488
Net increase in cash and cash equivalents	145,340			54,192			45,314			145,340
Cash and cash equivalents at the beginning of the period	543,789			338,366			333,558			543,789
Cash and cash equivalents at the end of the period	$	689,129		$	392,558		$	378,872		$	689,129

Non cash financing activities of continuing operations:
Settlement and exchange of convertible notes with common or treasury stock	$	958		$	5		$	—		$	958
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$	19,311		$	11		$	17,872		$	19,311

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)


	Common Stock			Additional Paid In Capital				Retained Earnings			Accumulated Other Comprehensive Loss				Treasury Stock							Total			Common Stock				Additional Paid In Capital				Retained Earnings				Accumulated Other Comprehensive Loss				Treasury Stock							Total
	Shares	Dollars					Shares				Accumulated Other Comprehensive Loss			Dollars				Shares			Dollars							Shares	Additional Paid In Capital			Dollars					Accumulated Other Comprehensive Loss											Total
																									(Dollars and shares in thousands, except per share)
Balance at December 31, 2016	45,814	$	45,814	Additional Paid In Capital			$	Retained Earnings	506,800		$	2,194,593			$	(438,717	)		1,741			Total		$	(170,973	)	$	2,137,517
Balance at December 31, 2017																									46,871		$	46,871	$	591,721			Retained Earnings		$	2,285,886			$	(265,091	)		1,704			$	(228,856	)		$	2,430,531
Cumulative effect adjustment resulting from the adoption of new accounting standards																																	2,110															2,110
Net income								40,170														40,170											56,184															56,184
Cash dividends ($0.34 per share)								(15,287		)												(15,287		)									(15,447		)													(15,447		)
Other comprehensive income											49,600											49,600															82,690											82,690
Settlements of convertible notes	928	928		3,890											—			30				4,848
Settlements of note hedges associated with convertible notes and warrants				19,311											119			(19,309		)		2							(17,884		)										(132	)		17,872				(12		)
Shares issued under compensation plans	53	53		(156		)									(41	)		2,069				1,966			97		97		992												(43	)		3,033				4,122
Deferred compensation															(2	)		88				88																			(8	)		322				322
Balance as of April 2, 2017	46,795	$	46,795	$	529,845			$	2,219,476		$	(389,117	)		1,817			$	(188,095	)		$	2,218,904
Balance as of April 1, 2018																									46,968		$	46,968	$	574,829			$	2,328,733			$	(182,401	)		1,521			$	(207,629	)		$	2,560,500

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 — Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements.

In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair ~~statement~~presentation of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017.

Note 2 — New accounting standards

In May 2014, the ~~FASB,~~Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. ~~The~~This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and ~~will affect~~affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those years. ~~Although~~The Company adopted the new standard on January 1, 2018 using the modified retrospective method applied to all contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $0.3 million increase to the Company's ~~evaluation~~opening balance of ~~this guidance is ongoing,~~retained earnings on the ~~Company's preliminary assessment indicates that~~adoption date. Also in connection with the adoption of the new standard, the Company reclassified the reserve for product returns from a contra-receivable to a liability. The reserve for returns and allowances was $4.4 million at April 1, 2018. The adoption of this guidance ~~will~~did not have a material impact on the ~~Company’s~~Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3.

In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for ~~capital and operating~~ leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements; the guidance provides certain practical expedients. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position.

In March 2016, the FASB issued new guidance designed to simplify several aspects of the accounting for share-based payment transactions, including, among other things, guidance related to accounting for income taxes, modification of the criteria for classification of awards as either equity awards or liability awards where an employer withholds shares from an employee's share-based award for tax withholding purposes, and classification on the statement of cash flows of cash payments to a tax authority by an employer that withholds shares from an employee's

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

award for tax withholding purposes. The Company adopted this standard as of January 1, 2017. The Company has applied the new guidance requiring recognition of excess tax deficiencies and tax benefits in the income statement, rather than in additional paid-in-capital, as previously required. The adoption of the new standard increased net income and cash flows from operating activities by $3.4 million ($0.07 diluted earnings per share) for the three months ended April 2, 2017. The Company will continue to estimate forfeitures of share-based awards at the time of grant, rather than recognize actual forfeitures as they occur, as permitted under the new guidance.

In August 2016, the FASB issued new guidance with regard to eight specific issues pertaining to the classification of certain cash receipts and cash payments within the statement of cash flows. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. The new guidance should generally be adopted using a retrospective transition method for each period presented. Although the Company's evaluation of this guidance is ongoing, the Company's preliminary assessment indicates that the adoption of this guidance will not have a material impact on the Company's cash flows.

In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The guidance is effective for annual periods beginning after December 15, ~~2017, and early adoption is permitted as of~~2017. The Company adopted the ~~beginning of an annual reporting period. The guidance should be applied~~new standard on aJanuary 1, 2018 using the modified retrospective ~~basis through~~method of adoption; as a ~~cumulative-effect adjustment~~result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings ~~as of~~on the ~~beginning of the annual period of adoption.~~adoption date. The ~~Company is currently evaluating the impact of the~~ adoption of this guidance ~~but currently does~~did not ~~anticipate the guidance will~~ have a material impact on ~~its~~the Company's consolidated ~~financial position or~~ results of ~~operations.~~

In January 2017, the FASB issued new guidance to clarify the definition of a “business,” with the objective of assisting entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or as an acquisition of a business. The definition of a business affects many areas of accounting, including acquisitions, disposals, goodwilloperations, cash flows and consolidation. The guidance generally defines a business as an integrated set of activities and assets (collectively referred to as a “set”) that is capable of being conducted and managed for the purpose of providing a return to investors or other owners, members, or participants. The guidance further provides that, to be considered a business, a set must meet specified requirements. However, the guidance also states that, if substantially all of the fair value of gross assets acquired (subject to specified exceptions) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not considered a business and no further analysis is required. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is permitted under specified circumstances.

In January 2017, the FASB issued guidance to simplify the quantitative test for goodwill impairment. Under current guidance, if a reporting unit’s carrying value exceeds its fair value, the entity must determine the implied value of goodwill. This determination is made by deducting the fair value of a reporting unit’s identifiable assets and liabilities from the fair value of the reporting unit as a whole as if the reporting unit had just been acquired. Under the new guidance, a determination of the implied value of goodwill will no longer be required; a goodwill impairment will be equal to the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The revised guidance is effective for fiscal years, and any interim goodwill impairment tests within those fiscal years, beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company is currently evaluating the impact of the adoption of this guidance, but currently does not anticipate the guidance will have a material impact on its consolidated financial ~~position or results of operations.~~position.

In March 2017, the FASB issued ~~new~~ guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The ~~new~~ guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017 and generally is required to be applied retrospectively. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements.

In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

the impact of the adoption of this guidance ~~but currently does not anticipate the guidance will have a material impact~~ on its consolidated results of ~~operations.~~operations and financial position.

In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits for a reclassification of these amounts to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted for reporting periods for which financial statements have not yet been issued. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.

From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the ~~Company’s~~its consolidated results of operations, cash flows or financial position.

Note 3 ~~— Acquisitions~~- Net revenues

~~On February 17, 2017,~~The Company primarily generates revenue from the ~~Company completed the acquisition~~sale of ~~Vascular Solutions, Inc. (“Vascular Solutions”) pursuant~~medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of ~~an Agreement and Plan~~a contract with the Company’s customer are satisfied; this occurs upon the transfer of Merger, dated as of December 1, 2016 (the "Merger Agreement"). Vascular Solutions is a medical device company that develops and markets products for use in minimally invasive coronary and peripheral vascular procedures. At the effective timecontrol of the ~~Merger (the “Effective Time”), each share~~products. Generally, transfer of common stock of Vascular Solutions (the “Shares”), other than Shares held by Vascular Solutions, Teleflex, or their respective subsidiaries, and Shares then held by a holder who has properly asserted dissenters’ rights under applicable law, was converted into the right to receive $56.00 per Share in cash, without interest and subject to applicable withholding tax (the “Merger Consideration”). In addition, each outstanding option or similar right to purchase Shares (other than pursuantcontrol to the ~~employee stock purchase program of Vascular Solutions) issued under~~customer occurs at the ~~Vascular Solutions’ Stock Option and Stock Award Plan (the "Company Options") was cancelled and converted into~~point in time when the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the exercise price of such Company Option, subject to applicable withholding tax. The aggregate consideration transferred was approximately $975.5 million, net of cash acquired.

Transaction expenses associated with the Vascular Solutions acquisition, which are included in selling, general and administrative expenses in the condensed consolidated statement of income were $8.9 million for the three months ended April 2, 2017. For the period from February 18, 2017 through April 2, 2017, the Company recorded post acquisition revenue and operating loss of $21.6 million and $14.8 million, respectively, related to Vascular Solutions. Financial information of Vascular Solutions is presented within the "All Other" category in the Company's presentation of segment information.

~~The transaction was financed utilizing borrowings under the Amended and Restated Credit Agreement, dated January 20, 2017 (the "Credit Agreement"), which is described in Note 7.~~

The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed as of February 17, 2017 with respect to the Vascular Solutions acquisition, which was accounted for as a business combination:

(Dollars in thousands)
Assets
Current assets $ 64,232
Property, plant and equipment 46,886
Intangible assets 539,250
Goodwill 521,396
Other assets 728
Total assets acquired 1,172,492
Less:
Current liabilities 13,470
Deferred tax liabilities 183,498
Liabilities assumed 196,968
Net assets acquired $ 975,524
Company’s

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

products are shipped from the manufacturing facility. The Company markets and sells products through its direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers such as pharmacies, which comprised 87%, 9% and 4% of consolidated net revenues, respectively, for the three months ended April 1, 2018. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. Payment is generally due 30 days from the date of invoice.

The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; and (5) the Company classifies shipping and handling costs within cost of goods sold.

The amount of consideration the Company receives and revenue the Company recognizes varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. The Company’s policy is to accept returns only in cases in which the product is defective and covered under the Company’s standard warranty provisions. When the Company gives customers the right to return products, the Company estimates the expected returns based on an analysis of historical experience. The reserve for returns and allowances was $4.4 million and $4.7 million as of April 1, 2018 and April 2, 2017, respectively. In estimating customer rebates, the Company considers the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers and other relevant information as the Company has a history of providing similar rebates on similar products to similar customers. The reserve for customer incentive programs, including customer rebates, was $13.2 million and $10.1 million at April 1, 2018 and April 2, 2017, respectively. The Company expects the amounts subject to the reserve as of April 1, 2018 to be paid within 90 days subsequent to period-end.

The following table disaggregates revenue by global product category for the three months ended April 1, 2018 and April 2, 2017.



	Three Months Ended
	April 1, 2018		April 2, 2017
Revenue by global product category_{(1) (2)}	(Dollars in thousands)
Vascular access	$	144,241	$	130,022
Anesthesia	85,418		81,205
Interventional	71,680		43,966
Surgical	85,632		87,304
Interventional urology	42,300		—
OEM	45,872		43,346
Other₍₃₎	112,087		102,038
Net revenues	$	587,230	$	487,881

(1)

The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined based on the particular products sold by the segments, and its non-North American reportable segments are defined based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

(2)

Products included within certain of the product categories listed in the table above differ from those included within the similarly named reportable segment. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which those sales originated, while the classification of products within the product categories listed above includes sales originating from multiple call points within the customer's organization.

(3) Other revenues in the table above comprise the Company’s respiratory, urology and cardiac product categories.

Note 4 — Acquisitions

During 2017, the Company completed several acquisitions; the largest of which were Vascular Solutions, Inc. ("Vascular Solutions") and NeoTract, Inc. ("NeoTract"), which are summarized below. The fair value of the consideration transferred for the 2017 acquisitions was $2.0 billion.

Vascular Solutions

On February 17, 2017, the Company acquired Vascular Solutions, a medical device company that developed and marketed products for use in minimally invasive coronary and peripheral vascular procedures. The aggregate consideration paid by the Company in connection with the acquisition was $975.5 million.

NeoTract

On October 2, 2017, the Company acquired NeoTract, a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The fair value of consideration transferred by the Company was $975.2 million, which included initial payments of $725.6 million in cash less a favorable working capital adjustment of $1.4 million (payment for which remains outstanding as of April 1, 2018) and $251.0 million in estimated fair value of contingent consideration related to revenue-based milestones. The contingent consideration liability represents the estimated fair value of the Company’s obligations, under the acquisition agreement, to make additional payments of up to $375 million in the aggregate if specified sales goals through the end of 2020 are achieved. Financial information of NeoTract is primarily presented within the Interventional Urology North America operating segment, which is included in the "all other" category in the Company's presentation of segment information.

The Company is continuing to evaluate the initial purchase price ~~allocation,~~allocations in connection with its acquisition of NeoTract, and further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities, certain intangible assets and goodwill. ~~The goodwill resulting from the acquisition primarily reflects synergies currently expected to be realized from the integration of the acquired business.~~

~~The following table sets forth the components of identifiable intangible assets acquired and the ranges of the useful lives as of the date of acquisition:~~

Fair value Useful life range
(Dollars in thousands) (Years)
Intellectual property 248,200
10- 20
In-process research and development ("IPR&D") 15,600
Indefinite
Trade names 16,650
20
Customer lists 258,800
25

Pro forma combined financial information

The following unaudited pro forma combined financial information for the three months ended April 2, 2017 ~~and March 27, 2016, respectively,~~ gives effect to the Vascular Solutions ~~acquisition~~and NeoTract acquisitions as if ~~it was completed at the beginning of each~~they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the ~~respective periods.~~results of operations that actually would have occurred under the ownership and management of the Company.

Three Months Ended
April 2, 2017 March 27, 2016
(Dollars and shares in thousands, except per share)
Net revenue $ 510,705
$ 464,124
Net income $ 26,247
$ 36,186
Basic earnings per common share:
Net income $ 0.58
$ 0.87
Diluted earnings per common share:
Net income $ 0.56
$ 0.74
Weighted average common shares outstanding:
Basic 44,893
41,647
Diluted 46,615
48,782

The unaudited pro forma combined financial information presented above includes the accounting effects of the business combination, including amortization charges from acquired intangible assets, adjustments for depreciation of property plant and equipment, interest expense, the revaluation of inventory and the related tax effects. The unaudited pro forma financial information for the three months ended April 2, 2017 includes non-recurring charges specifically related to the acquisition, including $23.8 million in combined acquisition costs of the Company and Vascular Solutions and $2.1 million in interest expense associated with a bridge loan facility that was put in place on December 1, 2016 to, among other things, assist the Company in financing the acquisition of Vascular Solutions. The bridge facility was not utilized, as the required financing was provided under the Credit Agreement.

The unaudited pro forma combined financial information for the three months ended March 27, 2016 reflects the historical results of Vascular Solutions based upon their respective reporting period for the three months ended March 31, 2016 and the effects of the pro forma adjustments listed above.

~~2016 acquisitions~~

The Company made the following acquisitions during 2016 (the "2016 acquisitions"), which, with the exception of its acquisition of the outstanding noncontrolling interest in Teleflex Medical Private Limited, were accounted for as business combinations:



	Three Months Ended
	April 2, 2017
	(Dollars and shares in thousands, except per share)
Net revenue	$	533,318
Net income	$	37,108
Basic earnings per common share:
Net income	$	0.83
Diluted earnings per common share:
Net income	$	0.80
Weighted average common shares outstanding:
Basic	44,893
Diluted	46,615

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

~~On September 2, 2016,~~The unaudited pro forma combined financial information presented above includes the Company acquired certain assets of CarTika Medical, Inc., ("CarTika"), an original equipment manufacturer (OEM) of catheters and other medical devices that complement the Company's OEM product portfolio.

On July 1, 2016, the Company, which previously owned a 74% controlling interest in its Indian affiliate, Teleflex Medical Private Limited, acquired the remaining 26% ownership interest from the noncontrolling shareholders. Teleflex Medical Private Limited is partaccounting effects of the Company's Asia reportable operating segment. As this acquisition did not result in a change in the Company's control of the entity, the Company recognized the $7.5 million excess of the purchase price of the noncontrolling interest over its carrying value as equity.

~~During the second quarter 2016, the Company acquired certain assets of two medical device~~Vascular Solutions and ~~supplies distributors in New Zealand.~~

~~The aggregate purchase price paid in connection with the 2016~~NeoTract acquisitions, was $22.8 million. The results of operations of the acquired businesses and assets are included in the condensed consolidated statements of income from their respective acquisition dates. Pro forma information is not presented, as the operations of the acquired businesses are not significantincluding, to the ~~overall operations~~extent applicable, amortization charges from acquired intangible assets; adjustments for depreciation of property, plant and equipment; interest expense; the ~~Company.~~revaluation of inventory; and the related tax effects. The unaudited pro forma financial information also includes non-recurring charges specifically related to the Vascular Solutions and NeoTract acquisitions.

Note 45 — Restructuring charges

The following tables provide information regarding restructuring charges recognized by the Company for the three months ended April 1, 2018 and April 2, ~~2017 and March 27, 2016 consisted of the following:~~2017:



Three Months Ended April 1, 2018
	Termination benefits		Other restructuring costs ₍₂₎		Total
	(Dollars in thousands)
2016 Footprint realignment plan	$	1,955	$	194	$	2,149
2014 Footprint realignment plan	116		8		124
Other restructuring programs ₍₁₎	585		205		790
Restructuring charges	$	2,656	$	407	$	3,063


Three Months Ended April 2, 2017
	Termination Benefits		Facility Closure Costs		Contract Termination Costs			Other Exit Costs		Total		Termination benefits		Other restructuring costs ₍₂₎			Total
	(Dollars in thousands)											(Dollars in thousands)
2017 Vascular Solutions Integration Program	$	4,482	$	—	$	—		$	—	$	4,482
2017 EMEA Restructuring Program	7,121		—		—			—		7,121
Vascular Solutions Integration Program												$	4,482	$	—		$	4,482
EMEA Restructuring Program												7,121		—			7,121
2016 Footprint realignment plan	539		12		(71		)	29		509		539		(30		)	509
2014 Footprint realignment plan	303		—		—			8		311		303		8			311
Other restructuring programs ⁽¹⁾⁽³⁾	305		47		130			40		522		305		217			522
Total restructuring charges	$	12,750	$	59	$	59		$	77	$	12,945
Restructuring charges												$	12,750	$	195		$	12,945

Three Months Ended March 27, 2016
Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total
(Dollars in thousands)
2016 Footprint realignment plan $ 10,347
$ —
$ —
$ —
$ 10,347
Other restructuring programs ⁽²⁾
(495 ) 123
(108 ) 101
(379 )
Total restructuring charges $ 9,852
$ 123
$ (108 ) 101
$ 9,968

(1)

Other restructuring programs in 2018 include the ~~2016 Other Restructuring programs~~Vascular Solutions integration program and the ~~2015 Restructuring~~EMEA restructuring program (both initiated in 2017) as well as the other 2016 restructuring programs. For a description of these ~~plans,~~programs, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, ~~2016.~~2017.


(2)	Other restructuring costs include facility closure, contract termination, and other exit costs.


(3)	Other restructuring programs in 2017 primarily includes the 2015 Restructuring programs, the 2014 Footprint Realignment plan and the 2012 Restructuring program. For a description of these plans, see Note 4 to the Company’s consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2016. other 2016 restructuring programs.

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

~~2017 Vascular Solutions Integration Program~~

During the first quarter 2017, the Company committed to a restructuring program related to the integration of Vascular Solutions into Teleflex. The Company initiated the program in the first quarter 2017 and expects the program to be substantially completed by the end of the second quarter 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $6.0 million to $7.5 million related to this program, of which $4.5 million to $5.3 million will constitute termination benefits, while $1.5 million to $2.2 million will relate to other exit costs including employee relocation and outplacement costs. Additionally, the Company expects to incur $2.5 million to $3.0 million of restructuring related charges consisting primarily of retention bonuses offered to certain employees expected to remain with the Company after completion of the program. All of these charges will result in future cash outlays.

~~2017 EMEA Restructuring Program~~

During the first quarter 2017, the Company committed to a restructuring program to centralize certain administrative functions in Europe. The program will commence in the second quarter 2017 and is expected to be substantially completed by the end of 2018. The Company estimates that it will record aggregate pre-tax restructuring charges of $7.1 million to $8.5 million related to this program, almost all of which constitute termination benefits, and all of which will result in future cash outlays.

~~2016 Other Restructuring Programs~~

During 2016, the Company committed to programs designed to improve operating efficiencies and reduce costs. The programs involve the consolidation of certain global administrative functions and manufacturing operations (the "Other 2016 restructuring programs"). The programs commenced in the second half of 2016 and are expected to be substantially complete by the end of the first quarter 2018. The Company estimates that it will record aggregate pre-tax charges of $3.8 million to $4.7 million related to these actions, substantially all of which constitute termination benefits that will result in future cash outlays. Additionally, the Company expects to incur approximately $1.5 million of accelerated depreciation and other costs directly related to these programs and anticipates that these costs to be recognized in cost of goods sold, of which, approximately $0.6 million is expected to result in future outlays.

~~As of April 2, 2017, the Company has a restructuring reserve of $1.7 million related to this program.~~

2016 Footprint Realignment Plan

In 2016, the Company initiated a restructuring plan (the “2016 ~~footprint~~Footprint realignment ~~plan’~~plan") ~~designed to reduce costs, improve operating efficiencies and enhance the Company’s long term competitive position. The plan involves~~involving the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 ~~footprint~~Footprint realignment plan of between approximately $34 million to $44 million, of which an estimated $27 million to $31 million are expected to result in future cash outlays. Most of these charges, and the related cash outlays, are expected to be made prior to the end of 2018.

In addition to the restructuring charges ~~outlined~~shown in the tables above, the Company recorded restructuring related charges with respect to the 2016 Footprint realignment plan of ~~$2.1~~$1.4 millionand ~~$0.6~~$2.1 million for the three months ended April 1, 2018 and April 2, 2017, ~~and March 27, 2016,~~ respectively, related to this plan, the majority of which constituted accelerated depreciation and other costs, principally for the transfer of manufacturing operations to the new locations. These costs were recognized primarily inwithin cost of goods sold.

As of April ~~2, 2017,~~1, 2018, the Company has incurred ~~net aggregate~~ restructuring charges ~~related to~~in connection with the 2016 Footprint realignment plan ~~of $13.0~~aggregating to $16.8 million. Additionally, as of April ~~2, 2017,~~1, 2018, the Company has incurred net aggregate accelerated depreciation and certain other costs, principally related to the transfer of manufacturing operations to new locations, of $8.5 million. These costs primarily were included in cost of goods sold. As of April 2, 2017, the Company has a restructuring ~~reserve of $8.9 million related to this plan, the majority of which relates to termination benefits.~~

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

related charges aggregating to $16.1 million related to the 2016 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. The restructuring related charges primarily were included in cost of goods sold. As of April 1, 2018, the Company has a restructuring reserve of $6.5 million related to this plan, all of which related to termination benefits.

2014 Footprint Realignment Plan

In 2014, the Company initiated a restructuring plan (“the 2014 ~~footprint~~Footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of ~~2020.The~~2020. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 ~~footprint~~Footprint realignment plan of approximately ~~$43~~$46 million to ~~$48~~$51 million, of which an estimated ~~$33~~$38 million to ~~$38~~$43 million are expected to result in future cash outlays. ~~These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020.~~ The Company expects to incur $24 million to $30 million in aggregate capital expenditures under the ~~plan~~.plan.

In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges with respect to the 2014 Footprint realignment plan of ~~$1.6~~$0.4 million and ~~$2.1~~$1.6 million for the three months ended April 1, 2018 andApril 2, 2017 ~~and March 27, 2016,~~ respectively, related to the 2014 footprint realignment plan, the majority of which constituted accelerated depreciation and other costs principally related to the transfer of manufacturing operations to new locations. These costs were recognized primarily inwithin cost of goods sold.

As of April ~~2, 2017,~~1, 2018, the Company has incurred ~~net aggregate~~ restructuring charges ~~related to~~in connection with the 2014 ~~footprint~~Footprint realignment plan ~~of $11.4~~aggregating to $11.9 million. Additionally, as of April ~~2, 2017,~~1, 2018, the Company has incurred ~~net aggregate~~restructuring related charges aggregating to $27.3 million related to the 2014 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally ~~for~~resulted from the transfer of manufacturing operations from the existing locations to ~~the~~ new ~~locations in connection with the plan of $24.5 million.~~locations. These ~~costs~~restructuring related charges primarily were included in cost of goods sold. As of April ~~2, 2017,~~1, 2018, the Company has a restructuring reserve of ~~$4.8~~$3.7 million in connection with the plan, all of which ~~relates~~related to termination benefits.

For additional information regarding the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, ~~2016.~~2017.

Restructuring charges by reportable operating segment, and by all other operating segments in the aggregate, for the three months ended April 1, 2018 and April 2, 2017 ~~and March 27, 2016~~ are set forth in the following table:


	Three Months Ended					Three Months Ended
	April 2, 2017		March 27, 2016			April 1, 2018		April 2, 2017
	(Dollars in thousands)					(Dollars in thousands)
Vascular North America						$	321	$	728
Interventional North America						545		4,215
Anesthesia North America						34		247
EMEA						251		7,527
All other						1,912		228
Restructuring charges						$	3,063	$	12,945
Vascular North America	$	748	$	4,163
Anesthesia North America	247		1,875
Surgical North America	—		(19		)
EMEA	7,500		3,872
Asia	—		2
OEM	—		4
All other	4,450		71
Total restructuring charges	$	12,945	$	9,968

Note 6 — Inventories, net

Inventories as of April 1, 2018 and December 31, 2017 consisted of the following:



	April 1, 2018		December 31, 2017
	(Dollars in thousands)
Raw materials	$	94,786	$	98,451
Work-in-process	66,185		62,381
Finished goods	242,705		234,912
Inventories, net	$	403,676	$	395,744

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

~~Note 5 — Inventories, net~~

~~Inventories as of April 2, 2017 and December 31, 2016 consisted of the following:~~

April 2, 2017 December 31, 2016
(Dollars in thousands)
Raw materials $ 92,172
$ 65,319
Work-in-process 60,063
54,555
Finished goods 203,054
196,297
Inventories, net $ 355,289
$ 316,171

Note 67 — Goodwill and other intangible assets, net

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the three months ended April ~~2, 2017:~~1, 2018:

Vascular
North America
Anesthesia
North America
Surgical
North America
EMEA
Asia OEM
All
Other
Total
(Dollars in thousands)
Balance as of December 31, 2016 $ 345,546

$ 141,253

$ 250,912

$ 290,041

$ 138,185
$ 4,883

$ 105,900

$ 1,276,720
Goodwill related to acquisitions —

—

—

—

—
—

521,396

521,396
Currency translation and other adjustments (1,590 )
93

—

11,186

5,735
—

1,958

17,382
Balance as of April 2, 2017 $ 343,956
$ 141,346
$ 250,912
$ 301,227
$ 143,920
$ 4,883
$ 629,254
$ 1,815,498



	Vascular North America		Interventional North America		Anesthesia North America		Surgical North America		EMEA		Asia		OEM		All Other		Total
	(Dollars in thousands)
December 31, 2017	$	264,869	$	433,049	$	157,289	$	250,912	$	494,548	$	209,200	$	4,883	$	420,842	$	2,235,592
Goodwill related to acquisitions	—		—		—		—		9		3		—		145		157
Currency translation adjustment	—		5,630		303		—		16,225		4,048		—		2,492		28,698
April 1, 2018	$	264,869	$	438,679	$	157,592	$	250,912	$	510,782	$	213,251	$	4,883	$	423,479	$	2,264,447

The ~~following table provides information as of April 2, 2017 and December 31, 2016 regarding the~~Company's gross carrying amount of, and accumulated amortization relating to, intangible assets ~~net:~~

Gross Carrying Amount Accumulated Amortization
April 2, 2017 December 31, 2016 April 2, 2017 December 31, 2016
(Dollars in thousands)
Customer relationships $ 885,648
$ 622,428
$ (248,033 ) $ (239,055 )
In-process research and development 32,689
16,532
—
—
Intellectual property 769,892
519,962
(213,843 ) (203,390 )
Distribution rights 23,185
23,021
(15,673 ) (15,239 )
Trade names 400,406
379,724
(15,357 ) (13,974 )
Non-compete agreements 2,771
2,692
(1,231 ) (1,038 )
$ 2,114,591
$ 1,564,359
$ (494,137 ) $ (472,696 )

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

~~Note 7 — Borrowings~~

~~The Company's borrowings at~~as of April ~~2, 2017~~1, 2018 and December 31, ~~2016~~2017 were as follows:

April 2, 2017 December 31, 2016
(Dollars in thousands)
Senior Credit Facility:
Revolving credit facility, at a rate of 2.46% at April 2, 2017, due 2022 $ 608,000
$ 210,000
Term loan facility, at a rate of 2.44% at April 2, 2017, due 2022 750,000
—
3.875% Convertible Senior Subordinated Notes due 2017 44,325
136,076
4.875% Senior Notes due 2026 400,000
400,000
5.25% Senior Notes due 2024 250,000
250,000
Securitization program, at a rate of 1.73% at April 2, 2017 50,000
50,000

2,102,325
1,046,076
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 (504 ) (2,707 )
Less: Unamortized debt issuance costs (12,929 ) (10,046 )
2,088,892

1,033,323
Current borrowings (131,095 ) (183,071 )
Long-term borrowings $ 1,957,797
$ 850,252

~~Amended and restated senior credit facility~~

On January 20, 2017, the Company entered into the Credit Agreement, which provides for a five year revolving credit facility of $1.0 billion and a term loan facility of $750.0 million. The obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of the material domestic subsidiaries of the Company and are secured by a lien on substantially all of the assets owned by the Company and each guarantor. The maturity date of the revolving credit facility under the Credit Agreement is January 20, 2022 and the term loan facility will mature on February 17, 2022.

At the Company’s option, loans under the Credit Agreement will bear interest at a rate equal to adjusted LIBOR plus an applicable margin ranging from 1.25% to 2.50% or at an alternate base rate, which is defined as the highest of (i) the publicly announced prime rate of JPMorgan Chase Bank, N.A., the administrative agent under the Credit Agreement, (ii) 0.5% above the federal funds rate and (iii) 1% above adjusted LIBOR for a one month interest period on such day, plus an applicable margin ranging from 0.25% to 1.50%, in each case subject to adjustment based on the Company’s consolidated total leverage ratio (generally, the ratio of Consolidated Total Funded Indebtedness to Consolidated EBITDA, each as defined in the Credit Agreement, for the four most recent fiscal quarters ending on or preceding the date of determination). Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00%.

The Company is required to maintain a maximum total consolidated leverage ratio of 4.50 to to 1.00 and a maximum consolidated senior secured leverage ratio (generally, Consolidated Senior Secured Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA for the four most recent quarters ending on or preceding the date of determination) of 3.50 to 1.00. The Company is further required to maintain a consolidated interest coverage ratio (generally, Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination to Consolidated Interest Expense, as defined in the Credit Agreement, paid in cash for such period) of not less than 3.50 to 1.00.

The Company capitalized $12.0 million related to transaction fees, including underwriters’ discounts and commissions, incurred in connection with the Credit Agreement. In addition, because the Company's entry into the Credit Agreement was considered a partial extinguishment of the indebtedness under its previously outstanding credit agreement, the Company recognized a loss on extinguishment of debt of $0.4 million for three months ended April 2, 2017.

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

~~3.875% Convertible Senior Subordinated Notes -~~ ~~Exchange Transactions~~

On January 5, 2017, pursuant to separate, privately negotiated agreements between the Company and certain holders (the "Holders") of its 3.875% Convertible Senior Subordinated Notes due 2017 (the "Convertible Notes"), the Company paid cash and common stock (the "Exchange Consideration") to the Holders in exchange for $91.7 million aggregate principal amount of the Convertible Notes (the "Exchange Transactions"). The Exchange Consideration paid to each of the Holders per $1,000 principal amount of Convertible Notes was equal to: (i) $1,000 in cash, (ii) a number of shares of the Company's common stock equal to the amount of the conversion value of the Convertible Notes in excess of the $1,000 principal amount (the "Conversion Shares"), calculated on the basis of the average daily volume weighted average price per share of Company common stock over a specified period (the "Average Daily VWAP"), (iii) an inducement payment in additional shares of common stock (the "Inducement Shares") calculated based on the Average Daily VWAP; and (iv) cash in an amount equal to accrued and unpaid interest to, but not including, the closing date. As a result of the Exchange Transactions, the Company paid the Holders aggregate cash consideration of approximately $93.2 million (which includes approximately $1.5 million in accrued but previously unpaid interest) and issued and delivered to the Holders approximately 0.93 million shares of Company common stock (including both Conversion Shares and Inducement Shares). The Company funded the $93.2 million cash payment constituting part of the Exchange Consideration through borrowings under its revolving credit facility. As a result of the Exchange Transactions, the Company recognized a loss on extinguishment of debt of $5.2 million.

In connection with its entry into the Exchange Transactions, the Company also entered into bond hedge unwind agreements (the "Hedge Unwind Agreements") and warrant unwind agreements (the "Warrant Unwind Agreements") with the dealer counterparties to the convertible note hedge transactions and warrant transactions that were effected at the time of the initial issuance of the Convertible Notes. Under the Hedge Unwind Agreements, the number of then-outstanding call options issued to the Company under the Convertible Note hedge transactions was reduced to reflect proportionately the reduction in the outstanding principal amount of the Convertible Notes following the Exchange Transactions. Under the Warrant Unwind Agreements, the number of warrants then held by the dealer counterparties also was reduced. On a net basis, after giving effect to the Hedge Unwind Agreements and Warrant Unwind Agreements, the Company received 0.12 million shares of Company common stock from the dealer counterparties.

~~Fair Value of Long-Term Borrowings~~

To determine the fair value of the debt categorized as Level 2 in the table below, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of April 2, 2017 and December 31, 2016, categorized by the level of inputs within the fair value hierarchy used to measure fair value (see Note 10, “Fair value measurement,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 for further information regarding the fair value hierarchy):

April 2, 2017 December 31, 2016
(Dollars in thousands)
Level 1 $ 140,389
$ 344,765
Level 2 2,015,793
929,362
Total $ 2,156,182
$ 1,274,127



	Gross Carrying Amount				Accumulated Amortization
	April 1, 2018		December 31, 2017		April 1, 2018			December 31, 2017
	(Dollars in thousands)
Customer relationships	$	1,044,509	$	1,023,837	$	(295,480	)	$	(281,263	)
In-process research and development	31,698		34,672		—			—
Intellectual property	1,312,598		1,287,487		(282,907		)	(258,580		)
Distribution rights	23,922		23,697		(17,490		)	(16,996		)
Trade names	578,646		571,510		(25,990		)	(22,069		)
Non-compete agreements	24,964		23,429		(3,915		)	(1,976		)
	$	3,016,337	$	2,964,632	$	(625,782	)	$	(580,884	)

Note 8 — Financial instruments

Foreign Currency Forward Contracts

The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. For the three months ended April 1, 2018 the Company recognized a gain related to non-designated foreign currency forward contracts of $0.6 million. For the three months ended April 2, 2017, ~~and March 27, 2016,~~ the Company recognized a loss related to non-designated foreign currency forward contracts of $0.8 ~~million and $0.3 million, respectively.~~million.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of April ~~2, 2017~~1, 2018 and December 31, ~~2016:~~2017:


	April 2, 2017		December 31, 2016		April 1, 2018		December 31, 2017
	Fair Value				Fair Value
	(Dollars in thousands)				(Dollars in thousands)
Asset derivatives:
Designated foreign currency forward contracts	$	2,054	$	667	$	1,989	$	914
Non-designated foreign currency forward contracts	152		490		198		307
Prepaid expenses and other current assets	$	2,206	$	1,157	$	2,187	$	1,221
Total asset derivatives	$	2,206	$	1,157	$	2,187	$	1,221
Liability derivatives:
Designated foreign currency forward contracts	$	1,589	$	2,139	$	993	$	1,373
Non-designated foreign currency forward contracts	303		118		455		53
Other current liabilities	$	1,892	$	2,257	$	1,448	$	1,426
Total liability derivatives	$	1,892	$	2,257	$	1,448	$	1,426

The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of April ~~2, 2017~~1, 2018 and December 31, ~~2016~~2017 was ~~$124.4~~$117.3 million and ~~$101.8~~$88.5 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of April ~~2, 2017~~1, 2018 and December 31, ~~2016~~2017 was ~~$79.3~~$111.5 million and ~~$73.4~~$110.6 million, respectively. All open foreign currency forward contracts as of April ~~2, 2017~~1, 2018 have durations of twelve months or less.

The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (loss) (“OCI”) for the three months ended April 2, 2017 and March 27, 2016:

After Tax Gain (Loss) Recognized in OCI
Three Months Ended
April 2, 2017 March 27, 2016
(Dollars in thousands)
Foreign currency forward contracts $ 1,728
$ 1,480

See Note 10 for information on the location in the condensed consolidated statements of income and amount of losses/(gains) attributable to derivatives that were reclassified from accumulated other comprehensive income (“AOCI”) to expense (income), net of tax.

There was no ineffectiveness related to the Company’s cash flow hedges during the three months ended April 1, 2018 and April 2, ~~2017 and March 27, 2016.~~2017.

Concentration of Credit Risk

Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. AHowever, a portion of the Company’s trade accounts receivable outside the United States, ~~however,~~ include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the creditworthiness of the healthcare systems in those countries and the financial stability of ~~their~~those countries' economies.

Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table ~~shows~~provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

current and long-term trade accounts receivable represented by these customers' trade accounts receivable at April ~~2, 2017~~1, 2018 and December 31, ~~2016:~~2017:

April 2, 2017
December 31, 2016

(Dollars in thousands)
Allowance for doubtful accounts(1)
$ 9,188
$ 8,630
Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal (2)
$ 46,272

$ 51,098
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 16.4 %
19.3 %



	April 1, 2018			December 31, 2017
	(Dollars in thousands)
Allowance for doubtful accounts ₍₁₎	$	9,865		$	10,255
Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal ₍₂₎	$	56,940		$	49,054
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal	16.3		%	14.6		%


~~(1)~~	~~The current portion of the allowance for doubtful accounts was $2.1 million and $2.0 million as of April 2, 2017 and December 31, 2016, respectively, and was recognized in accounts receivable, net.~~

(1) The current portion of the allowance for doubtful accounts was $3.1 million and $3.5 million as of April 1, 2018 and December 31, 2017, respectively, and was recognized in accounts receivable, net.


(2)	The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at April ~~2, 2017~~1, 2018 and December 31, ~~2016~~2017 was ~~$3.2~~$3.7 million and ~~$2.7~~$3.3 million, ~~respectively In January 2017, the Company sold $16.1 million of receivables outstanding with respect to publicly funded hospitals in Italy for $16.0 million.~~respectively.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

For the three months ended April 1, 2018 and April 2, 2017, ~~and March 27, 2016,~~ net revenues from customers in Greece, Italy, Spain and Portugal were ~~$31.5~~$38.3 million and ~~$30.9~~$31.5 million, respectively.

Note 9 — Fair value measurement

For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017.

The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of April ~~2, 2017~~1, 2018 and December 31, ~~2016:~~2017:


	Total carrying value at April 2, 2017		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)		Total carrying value at April 1, 2018		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
	(Dollars in thousands)								(Dollars in thousands)
Investments in marketable securities	$	8,048	$	8,048	$	—	$	—	$	8,989	$	8,989	$	—	$	—
Derivative assets	2,206		—		2,206		—		2,187		—		2,187		—
Derivative liabilities	1,892		—		1,892		—		1,448		—		1,448		—
Contingent consideration liabilities ⁽¹⁾	7,202		—		—		7,202		281,857		—		—		281,857


	Total carrying value at December 31, 2016		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)		Total carrying value at December 31, 2017		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
	(Dollars in thousands)								(Dollars in thousands)
Investments in marketable securities	$	7,660	$	7,660	$	—	$	—	$	9,045	$	9,045	$	—	$	—
Derivative assets	1,157		—		1,157		—		1,221		—		1,221		—
Derivative liabilities	2,257		—		2,257		—		1,426		—		1,426		—
Contingent consideration liabilities ⁽¹⁾	7,102		—		—		7,102		272,136		—		—		272,136


~~(1)~~	As of April 2, 2017 and December 31, 2016, $0.7 million and $0.6 million was recorded as the current portion of contingent consideration, respectively, and $6.5 million was recognized in other liabilities in the condensed consolidated balance sheet.

There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the three months ended April ~~2, 2017.~~1, 2018.

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

The following table provides information regarding changes, during the three months ended April 2, 2017, in Level 3 financial liabilities related to contingent consideration, which are described below in this Note 9 under "Valuation Techniques":

Contingent consideration
2017
(Dollars in thousands)
Balance - December 31, 2016 $ 7,102
Payment (79 )
Revaluations 179
Balance - April 2, 2017 $ 7,202

Valuation Techniques

The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices.

The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities as of the measurement date, based on quoted market prices, and taking into account the creditworthiness of the counterparties.

The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions.

Contingent consideration

As of April 1, 2018, the Company estimates that contingent consideration payments will occur in 2018 through 2029, and the maximum amount of undiscounted payments the Company could make under contingent consideration arrangements is $400.4 million. The contingent consideration liabilities, which primarily consist of Company ~~determines the~~obligations payable if specified net sales goals are achieved, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of ~~the liabilities for~~payment and project payment dates.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The contingent consideration ~~based on discounted cash flow analysis. This~~ fair value measurement is based on significant inputs ~~unobservable~~not observable in the market ~~primarily estimated sales royalties and the discount rate~~ and therefore ~~constitutes a~~constitute Level 3 ~~measurement~~inputs within the fair value hierarchy. The contingent consideration liability related to the NeoTract acquisition represents the estimated fair value of the Company's obligations to make payments of up to $375 million in the aggregate if specified sales goals are achieved. Specifically, the payments are based on net sales (as defined in the NeoTract acquisition agreement) for the periods from January 1, 2018 through April 30, 2018 and the years ended December 31, 2018, 2019 and 2020. The fair value of the contingent consideration related to the NeoTract acquisition was estimated using a Monte Carlo valuation approach, which simulates future revenues during the earn out-period using management's best estimates. The Company determines the value of its other contingent consideration liabilities based on a probability-weighted discounted cash flow analysis. Increases in projected revenues and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates may result in significantly lower fair value measurements; decreases in these items may have the opposite effect.

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition.

The following table provides information regarding changes, during the three months ended April 1, 2018, in Level 3 financial liabilities related to contingent consideration:



	Contingent consideration
	2018
	(Dollars in thousands)
Balance - December 31, 2017	$	272,136
Payment	(91		)
Revaluations	9,592
Translation adjustment	220
Balance - April 1, 2018	$	281,857

Note 10 — Shareholders’ equity

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:

Three Months Ended
April 2, 2017 March 27, 2016
(Shares in thousands)
Basic 44,893
41,647
Dilutive effect of share-based awards 821
519
Dilutive effect of 3.875% Convertible Notes and warrants ⁽¹⁾
901
6,616
Diluted 46,615
48,782


~~(1)~~	The reduction in the dilutive effect of the Convertible Notes and warrants at April 2, 2017 as compared to March 27, 2016 is due to the Company’s repurchase of Convertible Notes and conversions by holders of the Convertible Notes subsequent to March 27, 2016.

Weighted average shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.5 million and 5.2 million for the three months ended April 2, 2017 and March 27, 2016, respectively.



	Three Months Ended
	April 1, 2018	April 2, 2017
	(Shares in thousands)
Basic	45,329	44,893
Dilutive effect of share-based awards	1,044	821
Dilutive effect of convertible notes and warrants	322	901
Diluted	46,695	46,615

In connection with the issuance ~~of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge, consisting of call options held~~ by the Company ~~economically reduces the dilutive impact~~in 2010 of ~~the Convertible Notes. However, applicable accounting guidance requires~~convertible notes that matured in August 2017, and as part of hedging arrangements between the Company and two institutional counterparties, the Company issued warrants to ~~separately address~~ the ~~dilutive impact of~~counterparties, entitling them to purchase Company common stock. These transactions are described in greater detail in Note 11 to the ~~warrants issued under~~consolidated financial statements included in the ~~warrant agreements in computing diluted~~Company's Annual Report on Form

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

10-K for the year ended December 31, 2017. At April 1, 2018, warrants to purchase 374,418 shares at an exercise price of $74.65 per share remained outstanding. The remaining warrants expire ratably over a period ending on August 31, 2018. At April 1, 2018, the intrinsic value of the warrants (i.e. the excess of the aggregate market price of the underlying shares over the aggregate exercise price of the warrants) was $67.5 million.

The weighted average ~~shares outstanding, without giving effect to the anti-dilutive impact of the call options. The reduction in the~~ number of ~~diluted~~ shares that ~~would result~~were antidilutive and therefore excluded from ~~giving effect to~~ the ~~anti-dilutive impact~~calculation of ~~the call options would have been 0.5~~earnings per share were 0.6 million and ~~3.6~~0.5 million for the three months ended April ~~2, 2017~~1, 2018 and March 27, 2016, respectively. The treasury stock method is applied to the warrants because the average market price of the Company's common stock during the reporting periods presented exceeds the warrant exercise price of $74.65 per share, and assumes the proceeds from the exercise of the warrants are used by the Company to repurchase shares based on such average market price. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 0.4 million~~and 3.0 million for the three months ended~~ April 2, 2017, ~~and March 27, 2016,~~ respectively.

The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the three months ended April 1, 2018 and April 2, ~~2017 and March 27, 2016:~~2017:


	Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income			Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income
	(Dollars in thousands)												(Dollars in thousands)
Balance as of December 31, 2016	$	(2,424	)	$	(136,596	)	$	(299,697	)	$	(438,717	)
Balance as of December 31, 2017													$	340		$	(138,808	)	$	(126,623	)	$	(265,091	)
Other comprehensive income (loss) before reclassifications	350			(241		)	46,982			47,091			1,341			(478		)	81,188			82,051
Amounts reclassified from accumulated other comprehensive income	1,378			1,131			—			2,509			(720		)	1,359			—			639
Net current-period other comprehensive income	1,728			890			46,982			49,600			621			881			81,188			82,690
Balance as of April 2, 2017	$	(696	)	$	(135,706	)	$	(252,715	)	$	(389,117	)
Balance as of April 1, 2018													$	961		$	(137,927	)	$	(45,435	)	$	(182,401	)


	Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income			Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income
	(Dollars in thousands)												(Dollars in thousands)
Balance at December 31, 2015	$	(2,491	)	$	(138,887	)	$	(229,746	)	$	(371,124	)
Balance at December 31, 2016													$	(2,424	)	$	(136,596	)	$	(299,697	)	$	(438,717	)
Other comprehensive (loss) before reclassifications	(50		)	182			20,476			20,608			350			(241		)	46,982			47,091
Amounts reclassified from accumulated other comprehensive loss	1,530			1,056			—			2,586			1,378			1,131			—			2,509
Net current-period other comprehensive income	1,480			1,238			20,476			23,194			1,728			890			46,982			49,600
Balance at March 27, 2016	$	(1,011	)	$	(137,649	)	$	(209,270	)	$	(347,930	)
Balance at April 2, 2017													$	(696	)	$	(135,706	)	$	(252,715	)	$	(389,117	)

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three months ended April 1, 2018 and April 2, ~~2017 and March 27, 2016:~~2017:


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars in thousands)						(Dollars in thousands)
Losses on foreign exchange contracts:
(Gains) losses on foreign exchange contracts:
Cost of goods sold	$	1,645		$	1,871		$	(833	)	$	1,645
Total before tax	1,645			1,871			(833		)	1,645
Tax benefit	(267		)	(341		)
Taxes (benefit)							113			(267		)
Net of tax	$	1,378		$	1,530		$	(720	)	$	1,378
Amortization of pension and other postretirement benefit items:							Amortization of pension and other postretirement benefit items:
Actuarial losses ⁽¹⁾	$	1,726		$	1,622		$	1,746		$	1,726
Prior-service costs⁽¹⁾	29			14			24			29
Total before tax	1,755			1,636			1,770			1,755
Tax benefit	(624		)	(580		)	(411		)	(624		)
Net of tax	$	1,131		$	1,056		$	1,359		$	1,131

Total reclassifications, net of tax	$	2,509		$	2,586		$	639		$	2,509

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

~~Mezzanine Equity~~

As of December 31, 2016, the Company reclassified $1.8 million from additional paid-in capital to convertible notes in the mezzanine equity section of the Company's consolidated balance sheet. The reclassified amount represents the aggregate difference between the principal amount and the carrying value of the Convertible Notes purchased by the Company pursuant to the Exchange Transactions (see "3.875% Convertible Senior Subordinated Notes - Exchange Transactions" within Note 7) under agreements that were entered into prior to December 31,2016, but not consummated until January 5, 2017. ~~No reclassification was required as of April 2, 2017.~~

Note 11 — Taxes on income from continuing operations

Three Months Ended
April 2, 2017 March 27, 2016
Effective income tax rate (7.1)% 4.9%



	Three Months Ended
	April 1, 2018	April 2, 2017
Effective income tax rate	10.2%	(7.1)%

The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The legislation significantly changes U.S. tax law by, among other things, permanently reducing corporate income tax rates from a maximum of 35% to 21%, effective January 1, 2018; implementing a territorial tax system, by generally providing for, among other things, a dividends received deduction on the foreign source portion of dividends received from a foreign corporation if specified conditions are met; imposing two new U.S. base erosion provisions: (1) the global intangible low-taxed income ("GILTI") provisions and (2) the base erosion and anti-abuse tax ("BEAT") provisions; and imposing a one-time repatriation tax on undistributed post-1986 foreign subsidiary earnings and profits, which are deemed repatriated for purposes of the tax.

In accordance with the applicable provisions of SEC Staff Accounting Bulletin No. 118, the Company included in its consolidated financial statements as of December 31, 2017 provisional amounts reflecting the tax impact related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities. Once the Company's accounting for the income tax effects of the TCJA is complete, the amounts with respect to the income tax effects of the TCJA may differ from the provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the TCJA.

The effective income tax rate for the three months ended April 1, 2018 and April 2, 2017 was 10.2% and (7.1)%, respectively. The effective income tax rate for the three months ended April 1, 2018 includes the benefit of a lower U.S. corporate income tax rate of 21.0% from the enactment of the TCJA, partially offset by a tax cost associated with GILTI and other TCJA related changes. The effective income tax rate for the three months ended April 2, 2017 ~~and March 27, 2016 was (7.1)% and 4.9%, respectively. The effective income tax rate for the three months ended April 2, 2017, as compared to the first quarter 2016,~~ reflects ~~an excess~~a tax benefit associated with ~~share based payments, recognized under~~costs incurred in connection with the ~~new FASB guidance adopted by the Company as of January 1, 2017. In addition, the Company recognized discrete tax benefits associated the acquisition of~~ Vascular ~~Solutions. The effective tax rate for the three months ended March 27, 2016 reflects a tax benefit on the settlement of a foreign tax audit.~~Solutions acquisition.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 12 — Pension and other postretirement benefits

The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of April ~~2, 2017,~~1, 2018, no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement.

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

Net pension and other postretirement benefits expense (income) consist of the following:


	Pension Three Months Ended						Other Postretirement Benefits Three Months Ended				Pension Three Months Ended						Other Postretirement Benefits Three Months Ended
	April 2, 2017			March 27, 2016			April 2, 2017		March 27, 2016		April 1, 2018			April 2, 2017			April 1, 2018		April 2, 2017
	(Dollars in thousands)										(Dollars in thousands)
Service cost	$	717		$	652		$	74	$	111	$	378		$	717		$	52	$	74
Interest cost	3,785			3,920			378		406		3,722			3,785			378		378
Expected return on plan assets	(6,743		)	(6,198		)	—		—		(7,421		)	(6,743		)	—		—
Net amortization and deferral	1,690			1,579			65		57		1,707			1,690			62		65
Net benefits expense (income)	$	(551	)	$	(47	)	$	517	$	574	$	(1,614	)	$	(551	)	$	492	$	517

Note 13 — Commitments and contingent liabilities

Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At April ~~2, 2017,~~1, 2018, the Company has recorded ~~$1.1~~$1.0 million and ~~$5.6~~$5.7 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of April ~~2, 2017.~~1, 2018. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15-20 years.

Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment, environmental and other matters. As of April ~~2, 2017,~~1, 2018, the Company has recorded accrued liabilities of ~~$2.4~~$1.8 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. ~~Of the amount accrued as of April 2, 2017, $1.7 million pertains to discontinued operations.~~

During the first quarter 2017, Teleflex Medical Trading (Shanghai) Company, Ltd. (“Teleflex Shanghai”), one of the Company’s subsidiaries, eliminated a key distributor within its sales channel in China and undertook a distributor to direct sales conversion within that channel. On March 24, 2017, the distributor submitted an application for arbitration alleging, among other things, that Teleflex Shanghai wrongfully terminated its relationship with the distributor. The distributor is seeking $10.1 million (RMB 69.3 million) in damages for alleged costs of transportation and dismissal of personnel, as well as lost estimated profits. In addition, the distributor is seeking to compel Teleflex Shanghai to repurchase, for $9.1 million (RMB 63.0 million), Teleflex products that the distributor alleges are currently held in its inventory. Teleflex Shanghai intends to vigorously contest the distributor’s arbitration claim, and has filed a counterclaim seeking payment from the distributor of $8.9 million (RMB 61.2 million) in respect of outstanding trade receivables owed by the distributor to Teleflex Shanghai. At this time, the Company is unable to make an estimate of the amount of loss, if any, or range of possible loss that the Company could incur as a result of this matter.

In 2006, the Company was named as a defendant in a wrongful death product liability lawsuit filed in the Louisiana State District Court for the Parish of Calcasieu, involving a product manufactured by the Company’s former marine business. In September 2014, the case was tried before a jury, which returned a verdict in favor of the Company. The plaintiff subsequently filed a motion for a new trial, which was granted, and the case was re-tried before a jury in December 2014. On December 5, 2014, the jury returned a verdict in favor of the plaintiff, awarding $0.1 million in

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

compensatory damages and $23.0 million in punitive damages, plus pre- and post-judgment interest on the compensatory damages and post-judgment interest on the punitive damages. The Company filed an appeal with the Louisiana Court of Appeal, and the plaintiff filed a cross-appeal, seeking to overturn the trial court’s denial of pre-judgment interest on the punitive damages award. On June 29, 2016, the Louisiana Court of Appeal affirmed the trial court verdict in all respects. The Company and the plaintiff filed applications for a writ of certiorari (a request for review) to the Louisiana Supreme Court. On January 13, 2017, the Louisiana Supreme Court granted the Company's writ application. Oral arguments were held on May 1, 2017 and the parties currently are awaiting the court’s decision. As of April 2, 2017, the Company has accrued a liability representing its best estimate of probable loss associated with this matter, which is included in the Company’s accrued liabilities for litigation matters relating to discontinued operations discussed in the preceding paragraph. The Company believes that any liability arising from this matter that is not covered by the Company's product liability insurance will not exceed $10.0 million.

Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.

Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of April ~~2, 2017,~~1, 2018, the most significant tax examinations in process are in ~~Canada~~Germany, Italy, and ~~Germany.~~the United States. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts ~~its~~the reserves to address developments with respect to ~~these~~its uncertain tax ~~positions.~~positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions,

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.

Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Note 14 — Segment information

Following the Company's acquisition of Vascular Solutions, the Company commenced an integration program under which it is combining the Vascular Solutions' business with some of its legacy businesses. As a result, effective during the fourth quarter 2017, the Company realigned its operating segments. The changes to the operating segments were also made to reflect the manner in which the Company’s chief operating decision maker assesses business performance and allocates resources. The Company now has the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, the Company will continue to present certain operating segments, which currently include the Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because they are not material. All prior comparative periods presented have been restated to reflect these changes.

The following tables present the Company’s segment results for the three months ended April 1, 2018 and April 2, 2017:



	Three Months Ended
	April 1, 2018		April 2, 2017
	(Dollars in thousands)
Vascular North America	$	83,048	$	79,011
Interventional North America	60,196		39,946
Anesthesia North America	50,565		48,207
Surgical North America	40,677		45,944
EMEA	159,870		133,574
Asia	58,244		50,168
OEM	45,854		43,346
All other	88,776		47,685
Net revenues	$	587,230	$	487,881

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

~~Note 14 — Segment information~~

~~The following tables present the Company’s segment results for the three months ended April 2, 2017 and March 27, 2016:~~

Three Months Ended
April 2, 2017 March 27, 2016
(Dollars in thousands)
Revenue
Vascular North America $ 93,849
$ 81,588
Anesthesia North America 48,207
45,957
Surgical North America 45,944
38,941
EMEA 130,733
122,095
Asia 48,953
49,156
OEM 43,346
33,977
All other 76,849
53,179
Consolidated net revenues $ 487,881
$ 424,893


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars in thousands)						(Dollars in thousands)
Operating profit
Vascular North America	$	24,816		$	19,656		$	24,662		$	18,290
Interventional North America							14,120			(8,035		)
Anesthesia North America	13,527			12,177			17,333			13,304
Surgical North America	16,380			13,256			14,748			16,380
EMEA	22,240			21,043			31,770			21,310
Asia	10,798			13,008			13,368			10,884
OEM	9,121			5,189			9,016			9,121
All other	(6,301		)	5,743			(11,973		)	9,327
Total segment operating profit ⁽¹⁾	90,581			90,072			113,044			90,581
Unallocated expenses ⁽²⁾	(29,762		)	(22,575		)	(26,201		)	(29,762		)
Income from continuing operations before interest, loss on extinguishment of debt and taxes	$	60,819		$	67,497		$	86,843		$	60,819

(1)

Segment operating profit includes segment net revenues from external customers reduced by ~~its~~the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved.


(2)	Unallocated expenses primarily include manufacturing variances ~~with the exception of~~other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

The following table provides total net revenues by geographic region (based on the Company's selling location) for the three months ended April 1, 2018 and April 2, 2017:



	Three Months Ended
	April 1, 2018		April 2, 2017
	(Dollars in thousands)
United States	$	344,357	$	286,314
Europe	171,320		141,022
Asia	49,555		43,004
All other	21,998		17,541
Net revenues	$	587,230	$	487,881

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 15 — Condensed consolidating guarantor financial information

~~Teleflex Incorporated (the "Parent Company") is the issuer~~The Company’s $250 million principal amount of ~~its~~ 5.25% Senior Notes due 2024 (the ~~"2024 Notes"~~“2024 Notes”) ~~and~~, $400 million principal amount of 4.875% Senior Notes due 2026 (the ~~"2026~~“2026 Notes”) and $500 million principal amount of 4.625% Senior Notes due 2027 (the “2027 Notes," and collectively with the 2024 Notes and the 2026 Notes, the "Senior Notes")~~. Payment~~ are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the ~~2024~~Senior Notes ~~and 2026 Notes is~~are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The 2024 Notes, 2026 Notes and 2027 Notes are guaranteed by the same Guarantor Subsidiaries. The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three months ended April 1, 2018 and April 2, 2017, ~~and March 27, 2016,~~ condensed consolidating balance sheets as of April ~~2, 2017~~1, 2018 and December 31, ~~2016~~2017 and condensed consolidating statements of cash flows for the three months ended April 1, 2018 and April 2, 2017, ~~and March 27, 2016,~~ provide consolidated information for:



a.	Parent Company, the issuer of the guaranteed obligations;



b.	Guarantor Subsidiaries, on a combined basis;



c.	Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the ~~2024 Notes and 2026~~Senior Notes), on a combined basis; and



d.	Parent Company and its subsidiaries on a consolidated basis.

The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation.

Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries.

During the first quarter 2018, a Guarantor Subsidiary merged with and into Parent; the transaction was reflected as of the beginning of the earliest period presented in the condensed consolidating financial statements.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME ~~(LOSS)~~


	Three Months Ended April 2, 2017														Three Months Ended April 1, 2018
	Parent Company			Guarantor Subsidiaries			Non-Guarantor Subsidiaries		Eliminations			Condensed Consolidated			Parent Company			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Condensed Consolidated
	(Dollars in thousands)														(Dollars in thousands)
Net revenues	$	—		$	315,643		$	276,315	$	(104,077	)	$	487,881		$	—		$	379,419	$	320,009	$	(112,198	)	$	587,230
Cost of goods sold	—			192,001			143,896		(103,576		)	232,321			—			217,604		142,008		(103,652		)	255,960
Gross profit	—			123,642			132,419		(501		)	255,560			—			161,815		178,001		(8,546		)	331,270
Selling, general and administrative expenses	20,519			94,043			48,844		563			163,969			9,181			130,914		75,771		(529		)	215,337
Research and development expenses	235			11,186			6,406		—			17,827			227			19,368		6,432		—			26,027
Restructuring charges	—			5,374			7,571		—			12,945			—			908		2,155		—			3,063
(Loss) income from continuing operations before interest, extinguishment of debt and taxes	(20,754		)	13,039			69,598		(1,064		)	60,819
(Loss) income from continuing operations before interest and taxes															(9,408		)	10,625		93,643		(8,017		)	86,843
Interest, net	47,674			(30,963		)	846		—			17,557			22,141			2,931		598		—			25,670
Loss on extinguishment of debt	5,582			—			—		—			5,582
(Loss) income from continuing operations before taxes	(74,010		)	44,002			68,752		(1,064		)	37,680			(31,549		)	7,694		93,045		(8,017		)	61,173
(Benefit) taxes on (loss) income from continuing operations	(29,907		)	14,485			12,229		524			(2,669		)	(13,192		)	6,423		14,177		(1,166		)	6,242
Equity in net income of consolidated subsidiaries	84,452			55,802			216		(140,470		)	—			74,567			76,876		293		(151,736		)	—
Income from continuing operations	40,349			85,319			56,739		(142,058		)	40,349			56,210			78,147		79,161		(158,587		)	54,931
Operating loss from discontinued operations	(282		)	—			—		—			(282		)
Benefit on loss from discontinued operations	(103		)	—			—		—			(103		)
Loss from discontinued operations	(179		)	—			—		—			(179		)
Operating (loss) income from discontinued operations															(44		)	—		1,279		—			1,235
Tax benefit on loss from discontinued operations															(18		)	—		—		—			(18		)
(Loss) income from discontinued operations															(26		)	—		1,279		—			1,253
Net income	40,170			85,319			56,739		(142,058		)	40,170			56,184			78,147		80,440		(158,587		)	56,184
Other comprehensive income	49,600			49,404			53,901		(103,305		)	49,600			82,690			70,119		87,227		(157,346		)	82,690
Comprehensive income	$	89,770		$	134,723		$	110,640	$	(245,363	)	$	89,770		$	138,874		$	148,266	$	167,667	$	(315,933	)	$	138,874

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)



	Three Months Ended March 27, 2016															Three Months Ended April 2, 2017
	Parent Company			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Condensed Consolidated			Parent Company			Guarantor Subsidiaries			Non-Guarantor Subsidiaries		Eliminations			Condensed Consolidated
	(Dollars in thousands)															(Dollars in thousands)
Net revenues	$	—		$	258,911		$	261,348		$	(95,366	)	$	424,893		$	—		$	315,643		$	276,315	$	(104,077	)	$	487,881
Cost of goods sold	—			155,541			132,963			(88,758		)	199,746			—			192,001			143,896		(103,576		)	232,321
Gross profit	—			103,370			128,385			(6,608		)	225,147			—			123,642			132,419		(501		)	255,560
Selling, general and administrative expenses	9,329			81,477			45,059			483			136,348			20,519			94,043			48,844		563			163,969
Research and development expenses	—			6,435			5,918			—			12,353			235			11,186			6,406		—			17,827
Restructuring charges	—			4,758			5,210			—			9,968			—			5,374			7,571		—			12,945
Gain on sale of assets	—			—			(1,019		)	—			(1,019		)
(Loss) income from continuing operations before interest and taxes	(9,329		)	10,700			73,217			(7,091		)	67,497
(Loss) income from continuing operations before interest, extinguishment of debt and taxes																(20,754		)	13,039			69,598		(1,064		)	60,819
Interest, net	33,044			(20,318		)	978			—			13,704			24,273			(7,562		)	846		—			17,557
Loss on extinguishment of debt																5,582			—			—		—			5,582
(Loss) income from continuing operations before taxes	(42,373		)	31,018			72,239			(7,091		)	53,793			(50,609		)	20,601			68,752		(1,064		)	37,680
(Benefit) taxes on (loss) income from continuing operations	(15,848		)	11,677			7,864			(1,080		)	2,613			(21,333		)	5,911			12,229		524			(2,669		)
Equity in net income of consolidated subsidiaries	77,457			57,900			168			(135,525		)	—			69,625			55,802			216		(125,643		)	—
Income from continuing operations	50,932			77,241			64,543			(141,536		)	51,180			40,349			70,492			56,739		(127,231		)	40,349
Operating loss from discontinued operations	(382		)	—			—			—			(382		)	(282		)	—			—		—			(282		)
(Benefit) taxes on loss from discontinued operations	(139		)	—			69			—			(70		)
Tax benefit on loss from discontinued operations																(103		)	—			—		—			(103		)
Loss from discontinued operations	(243		)	—			(69		)	—			(312		)	(179		)	—			—		—			(179		)
Net income	50,689			77,241			64,474			(141,536		)	50,868			40,170			70,492			56,739		(127,231		)	40,170
Less: Income from continuing operations attributable to noncontrolling interest	—			—			179			—			179
Net income attributable to common shareholders	50,689			77,241			64,295			(141,536		)	50,689
Other comprehensive income attributable to common shareholders	23,194			18,573			22,412			(40,985		)	23,194
Comprehensive income attributable to common shareholders	$	73,883		$	95,814		$	86,707		$	(182,521	)	$	73,883
Other comprehensive income																49,600			49,404			53,901		(103,305		)	49,600
Comprehensive income																$	89,770		$	119,896		$	110,640	$	(230,536	)	$	89,770

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATING BALANCE SHEETS


	April 2, 2017											April 1, 2018
	Parent Company		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Condensed Consolidated		Parent Company		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Condensed Consolidated
	(Dollars in thousands)											(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	153,100	$	7,593	$	528,436	$	—		$	689,129	$	28,407	$	10,200	$	340,265	$	—		$	378,872
Accounts receivable, net	2,215		34,464		241,897		4,296			282,872		2,822		35,826		315,300		5,192			359,140
Accounts receivable from consolidated subsidiaries	8,025		2,238,256		338,230		(2,584,511		)	—		25,239		994,384		346,925		(1,366,548		)	—
Inventories, net	—		222,619		158,358		(25,688		)	355,289		—		246,289		192,343		(34,956		)	403,676
Prepaid expenses and other current assets	14,084		9,477		20,340		3,337			47,238		15,470		12,482		21,064		3,982			52,998
Prepaid taxes	11,072		—		9,527		—			20,599		—		—		7,234		—			7,234
Assets held for sale												—		3,239		—		—			3,239
Total current assets	188,496		2,512,409		1,296,788		(2,602,566		)	1,395,127		71,938		1,302,420		1,223,131		(1,392,330		)	1,205,159
Property, plant and equipment, net	2,517		207,818		144,899		—			355,234		2,340		205,115		182,064		—			389,519
Goodwill	—		1,228,353		587,145		—			1,815,498		—		1,247,150		1,017,297		—			2,264,447
Intangibles assets, net	—		1,167,974		452,480		—			1,620,454		—		1,333,983		1,056,572		—			2,390,555
Investments in consolidated subsidiaries												5,963,828		1,827,988		19,723		(7,811,539		)	—
Deferred tax assets	72,621		—		5,434		(76,092		)	1,963		—		—		6,230		(2,261		)	3,969
Notes receivable and other amounts due from consolidated subsidiaries	1,321,595		2,151,605		—		(3,473,200		)	—		2,171,364		2,189,631		—		(4,360,995		)	—
Other assets	7,203,940		1,578,527		30,859		(8,769,166		)	44,160		30,864		6,426		9,661		—			46,951
Total assets	$	8,789,169	$	8,846,686	$	2,517,605	$	(14,921,024	)	$	5,232,436	$	8,240,334	$	8,112,713	$	3,514,678	$	(13,567,125	)	$	6,300,600
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	81,095	$	—	$	50,000	$	—		$	131,095	$	27,500	$	—	$	50,000	$	—		$	77,500
Accounts payable	4,335		40,095		37,588		—			82,018		2,954		45,416		36,316		—			84,686
Accounts payable to consolidated subsidiaries	2,290,413		255,530		38,568		(2,584,511		)	—		1,014,612		275,625		76,311		(1,366,548		)	—
Accrued expenses	19,473		26,116		36,801		—			82,390		20,314		33,152		47,662		—			101,128
Current portion of contingent consideration	—		669		—		—			669		—		162,061		—		—			162,061
Payroll and benefit-related liabilities	16,858		15,707		33,362		—			65,927		15,618		24,212		40,588		—			80,418
Accrued interest	12,657		—		29		—			12,686		20,463		—		40		—			20,503
Income taxes payable	—		—		7,519		524			8,043		936		—		13,730		(1,166		)	13,500
Other current liabilities	1,926		4,153		3,451		—			9,530		1,466		5,355		5,157		—			11,978
Total current liabilities	2,426,757		342,270		207,318		(2,583,987		)	392,358		1,103,863		545,821		269,804		(1,367,714		)	551,774
Long-term borrowings	1,957,797		—		—		—			1,957,797		2,154,217		—		—		—			2,154,217
Deferred tax liabilities	—		504,454		32,292		(76,092		)	460,654		88,632		270,305		260,035		(2,261		)	616,711
Pension and postretirement benefit liabilities	82,623		31,223		16,380		—			130,226		66,986		32,393		18,495		—			117,874
Noncurrent liability for uncertain tax positions	1,432		13,731		2,776		—			17,939		1,396		8,237		2,995		—			12,628
Notes payable and other amounts due to consolidated subsidiaries	2,076,792		1,203,358		193,050		(3,473,200		)	—		2,114,287		2,048,841		197,867		(4,360,995		)	—
Noncurrent contingent consideration												—		108,727		11,069		—			119,796
Other liabilities	24,864		15,770		13,924		—			54,558		150,453		5,802		10,845		—			167,100
Total liabilities	6,570,265		2,110,806		465,740		(6,133,279		)	3,013,532		5,679,834		3,020,126		771,110		(5,730,970		)	3,740,100
Total shareholders' equity	2,218,904		6,735,880		2,051,865		(8,787,745		)	2,218,904		2,560,500		5,092,587		2,743,568		(7,836,155		)	2,560,500
Total liabilities and shareholders' equity	$	8,789,169	$	8,846,686	$	2,517,605	$	(14,921,024	)	$	5,232,436	$	8,240,334	$	8,112,713	$	3,514,678	$	(13,567,125	)	$	6,300,600

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)


	December 31, 2016											December 31, 2017
	Parent Company		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Condensed Consolidated		Parent Company		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Condensed Consolidated
	(Dollars in thousands)											(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	14,571	$	1,031	$	528,187	$	—		$	543,789	$	37,803	$	8,933	$	286,822	$	—		$	333,558
Accounts receivable, net	2,551		8,768		255,815		4,859			271,993		2,414		57,818		280,980		4,663			345,875
Accounts receivable from consolidated subsidiaries	4,861		2,176,059		309,149		(2,490,069		)	—		14,478		1,177,246		343,115		(1,534,839		)	—
Inventories, net	—		200,852		140,406		(25,087		)	316,171		—		245,533		176,490		(26,279		)	395,744
Prepaid expenses and other current assets	14,239		5,332		17,474		3,337			40,382		14,874		9,236		19,790		3,982			47,882
Prepaid taxes	—		—		7,766		413			8,179		—		—		5,748		—			5,748
Assets held for sale	—		—		2,879		—			2,879
Total current assets	36,222		2,392,042		1,261,676		(2,506,547		)	1,183,393		69,569		1,498,766		1,112,945		(1,552,473		)	1,128,807
Property, plant and equipment, net	2,566		163,847		136,486		—			302,899		2,088		213,663		167,248		—			382,999
Goodwill	—		708,546		568,174		—			1,276,720		—		1,246,144		989,448		—			2,235,592
Intangibles assets, net	—		640,999		450,664		—			1,091,663		—		1,355,275		1,028,473		—			2,383,748
Investments in consolidated subsidiaries												5,806,244		1,674,077		19,620		(7,499,941		)	—
Deferred tax assets	73,051		—		5,185		(76,524		)	1,712		—		—		6,071		(2,261		)	3,810
Notes receivable and other amounts due from consolidated subsidiaries	1,387,615		2,085,538		—		(3,473,153		)	—		2,452,101		2,231,832		—		(4,683,933		)	—
Other assets	6,044,337		1,525,285		29,962		(7,564,758		)	34,826		31,173		6,397		8,966		—			46,536
Total assets	$	7,543,791	$	7,516,257	$	2,452,147	$	(13,620,982	)	$	3,891,213	$	8,361,175	$	8,226,154	$	3,332,771	$	(13,738,608	)	$	6,181,492
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	133,071	$	—	$	50,000	$	—		$	183,071	$	36,625	$	—	$	50,000	$	—		$	86,625
Accounts payable	4,540		30,924		33,936		—			69,400		4,269		46,992		40,766		—			92,027
Accounts payable to consolidated subsidiaries	2,242,814		214,203		33,052		(2,490,069		)	—		1,211,568		261,121		62,150		(1,534,839		)	—
Accrued expenses	16,827		18,126		30,196		—			65,149		17,957		31,827		47,069		—			96,853
Current portion of contingent consideration	—		587		—		—			587		—		74,224		—		—			74,224
Payroll and benefit-related liabilities	20,610		26,672		35,397		—			82,679		21,145		44,009		42,261		—			107,415
Accrued interest	10,429		—		21		—			10,450		6,133		—		32		—			6,165
Income taxes payable	1,246		—		6,577		85			7,908		4,352		—		7,162		—			11,514
Other current liabilities	2,262		3,643		2,497		—			8,402		1,461		3,775		3,817		—			9,053
Total current liabilities	2,431,799		294,155		191,676		(2,489,984		)	427,646		1,303,510		461,948		253,257		(1,534,839		)	483,876
Long-term borrowings	850,252		—		—		—			850,252		2,162,927		—		—		—			2,162,927
Deferred tax liabilities	—		316,526		31,375		(76,524		)	271,377		88,512		265,426		251,999		(2,261		)	603,676
Pension and postretirement benefit liabilities	85,645		31,561		15,856		—			133,062		70,860		32,750		17,800		—			121,410
Noncurrent liability for uncertain tax positions	1,169		13,684		2,667		—			17,520		1,117		8,196		2,983		—			12,296
Notes payable and other amounts due to consolidated subsidiaries	2,011,737		1,264,004		197,412		(3,473,153		)	—		2,155,146		2,320,611		208,176		(4,683,933		)	—
Noncurrent contingent consideration												—		186,923		10,989		—			197,912
Other liabilities	23,848		15,695		12,472		—			52,015		148,572		7,850		12,442		—			168,864
Total liabilities	5,404,450		1,935,625		451,458		(6,039,661		)	1,751,872		5,930,644		3,283,704		757,646		(6,221,033		)	3,750,961
Convertible notes - redeemable equity component	1,824		—		—		—			1,824
Mezzanine equity	1,824		—		—		—			1,824
Total shareholders' equity	2,137,517		5,580,632		2,000,689		(7,581,321		)	2,137,517		2,430,531		4,942,450		2,575,125		(7,517,575		)	2,430,531
Total liabilities and shareholders' equity	$	7,543,791	$	7,516,257	$	2,452,147	$	(13,620,982	)	$	3,891,213	$	8,361,175	$	8,226,154	$	3,332,771	$	(13,738,608	)	$	6,181,492

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS


	Three Months Ended April 2, 2017															Three Months Ended April 1, 2018
	Parent Company			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Condensed Consolidated			Parent Company			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Condensed Consolidated
	(Dollars in thousands)															(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(86,020	)	$	158,343		$	80,535		$	(61,918	)	$	90,940		$	(108,377	)	$	134,198		$	61,027		$	86,848
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(155		)	(2,206		)	(10,533		)	—			(12,894		)	(159		)	(5,015		)	(10,573		)	(15,747		)
Proceeds from sale of assets	—			—			6,332			—			6,332
Payments for businesses and intangibles acquired, net of cash acquired	(975,524		)	—			—			—			(975,524		)	—			—			(3,684		)	(3,684		)
Net cash used in investing activities from continuing operations	(975,679		)	(2,206		)	(4,201		)	—			(982,086		)	(159		)	(5,015		)	(14,257		)	(19,431		)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	1,194,500			—			—			—			1,194,500
Reduction in borrowings	(138,251		)	—			—			—			(138,251		)	(18,500		)	—			—			(18,500		)
Debt extinguishment, issuance and amendment fees	(19,114		)	—			—			—			(19,114		)	(74		)	—			—			(74		)
Net proceeds from share based compensation plans and the related tax impacts	(505		)	—			—			—			(505		)	1,400			—			—			1,400
Payments for contingent consideration	—			(79		)	—			—			(79		)	—			(91		)	—			(91		)
Dividends paid	(15,287		)	—			—			—			(15,287		)	(15,447		)	—			—			(15,447		)
Intercompany transactions	179,151			(149,496		)	(29,655		)	—			—			131,967			(127,825		)	(4,142		)	—
Intercompany dividends paid	—			—			(61,918		)	61,918			—
Net cash provided by (used in) financing activities from continuing operations	1,200,494			(149,575		)	(91,573		)	61,918			1,021,264			99,346			(127,916		)	(4,142		)	(32,712		)
Cash flows from discontinued operations:
Net cash used in operating activities	(266		)	—			—			—			(266		)	(206		)	—			—			(206		)
Net cash used in discontinued operations	(266		)	—			—			—			(266		)	(206		)	—			—			(206		)
Effect of exchange rate changes on cash and cash equivalents	—			—			15,488			—			15,488			—			—			10,815			10,815
Net increase in cash and cash equivalents	138,529			6,562			249						145,340
Net (decrease) increase in cash and cash equivalents																(9,396		)	1,267			53,443			45,314
Cash and cash equivalents at the beginning of the period	14,571			1,031			528,187			—			543,789			37,803			8,933			286,822			333,558
Cash and cash equivalents at the end of the period	$	153,100		$	7,593		$	528,436		$	—		$	689,129		$	28,407		$	10,200		$	340,265		$	378,872

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)


	Three Months Ended March 27, 2016												Three Months Ended April 2, 2017
	Parent Company			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Condensed Consolidated			Parent Company			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Condensed Consolidated
	(Dollars in thousands)												(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(18,852	)	$	25,624		$	60,060		$	66,832		$	(86,020	)	$	158,343		$	80,535		$	(61,918	)	$	90,940
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(5		)	(3,470		)	(4,347		)	(7,822		)	(155		)	(2,206		)	(10,533		)	—			(12,894		)
Proceeds from sale of assets	—			—			1,251			1,251			—			—			6,332			—			6,332
Payments for businesses and intangibles acquired, net of cash acquired													(975,524		)	—			—			—			(975,524		)
Net cash used in investing activities from continuing operations	(5		)	(3,470		)	(3,096		)	(6,571		)	(975,679		)	(2,206		)	(4,201		)	—			(982,086		)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings													1,194,500			—			—			—			1,194,500
Reduction in borrowings	(9		)	—			—			(9		)	(138,251		)	—			—			—			(138,251		)
Debt extinguishment, issuance and amendment fees													(19,114		)	—			—			—			(19,114		)
Net proceeds from share based compensation plans and the related tax impacts	3,180			—			—			3,180			(505		)	—			—			—			(505		)
Payments for contingent consideration	—			(61		)	—			(61		)	—			(79		)	—			—			(79		)
Dividends paid	(14,179		)	—			—			(14,179		)	(15,287		)	—			—			—			(15,287		)
Intercompany transactions	32,371			(21,088		)	(11,283		)	—			179,151			(149,496		)	(29,655		)	—			—
Intercompany dividends paid													—			—			(61,918		)	61,918			—
Net cash provided by (used in) financing activities from continuing operations	21,363			(21,149		)	(11,283		)	(11,069		)	1,200,494			(149,575		)	(91,573		)	61,918			1,021,264
Cash flows from discontinued operations:
Net cash used in operating activities	(126		)	—			—			(126		)	(266		)	—			—			—			(266		)
Net cash used in discontinued operations	(126		)	—			—			(126		)	(266		)	—			—			—			(266		)
Effect of exchange rate changes on cash and cash equivalents	—			—			5,126			5,126			—			—			15,488			—			15,488
Net increase in cash and cash equivalents	2,380			1,005			50,807			54,192			138,529			6,562			249			—			145,340
Cash and cash equivalents at the beginning of the period	21,612			—			316,754			338,366			14,571			1,031			528,187			—			543,789
Cash and cash equivalents at the end of the period	$	23,992		$	1,005		$	367,561		$	392,558		$	153,100		$	7,593		$	528,436		$	—		$	689,129

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 16 — Subsequent event

On May 1, 2018, the Company initiated a restructuring plan involving the relocation of certain manufacturing operations to an existing lower-cost location, the outsourcing of certain of the Company’s distribution operations, and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to commence in the second quarter 2018 and are expected to be substantially completed by the end of 2024. The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan:



Type of expense	Total estimated amount expected to be incurred
Termination benefits	$60 million to $70 million
Other exit costs ₍₁₎	$2 million to $4 million
Restructuring charges	$62 million to $74 million
Restructuring related charges ₍₂₎	$40 million to $59 million
Total restructuring and restructuring related charges	$102 million to $133 million


(1)	Includes contract termination costs as well as facility closure and other exit costs (employee relocation costs, equipment relocation costs and outplacement).

(2)

Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new location, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold.

The Company estimates $99 million to $127 million of the restructuring and restructuring related charges will result in future cash outlays. Additionally, the Company expects that it will incur $19 million to $23 million in aggregate capital expenditures under the plan. The Company expects to incur most of these charges and cash outlays prior to 2024.

As the 2018 Footprint realignment plan progresses, management will reevaluate the estimated expenses and charges set forth above, and may revise its estimates, as appropriate, consistent with GAAP.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

All statements made in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks ~~uncertainties~~ and ~~assumptions~~uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from ~~what is~~those expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our ~~ability~~inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; our ~~ability~~inability to effectively execute our restructuring programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, sovereign debt issues and the impact of the United Kingdom’s vote to leave the European Union; difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to our business, see Item 1A, of"Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

Overview

Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.

We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve ~~eliminating~~our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct conversions ~~enable us~~are designed to ~~obtain~~facilitate improved product pricing and more direct access to the end users of our products within the sales channel.

On May 1, 2018, we initiated a restructuring plan involving the relocation of certain manufacturing operations to an existing lower-cost location, the outsourcing of certain distribution operations and related workforce reductions (the "2018 Footprint realignment plan). See "Result of Operations - Restructuring charges" below and Note 16 to the condensed consolidated financial statements included in this report for additional information.

On February 17, 2017, ~~the Company~~we acquired Vascular Solutions, Inc. (“Vascular Solutions”) ~~for $975.5 million net of cash acquired. Vascular Solutions is~~, a medical device company that ~~develops~~developed and ~~markets~~marketed clinical products for use in minimally invasive coronary and peripheral vascular ~~procedures.~~procedures, for an aggregate purchase price of $975.5 million. The acquisition is expected to meaningfully accelerate the growth of our vascular and interventional access product portfolios by facilitating our ~~entry~~further expansion into the coronary and peripheral vascular market, and by generating increased cross-portfolio selling opportunities to both our and Vascular Solutions' customer bases. ~~We financed~~

On October 2, 2017, we acquired NeoTract, Inc. ("NeoTract"), a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The fair value of the consideration we transferred to acquire NeoTract was $975.2 million, which included initial payments of $725.6 million in cash less a favorable working capital adjustment of $1.4 million (payment for which remains outstanding as of April 1, 2018) and $251.0 million, constituting the estimated fair value of contingent consideration. The contingent consideration liability represents the estimated fair value of our obligations, under the acquisition agreement, to make additional payments of up to $375 million in the aggregate if specified net sales goals through ~~a combination~~the end of borrowings under our revolving credit facility, which was increased in anticipation of the acquisition, and a new senior secured term loan facility, both of which were provided under our amended and restated credit agreement (the "Credit Agreement"), which is described in more detail below under "~~Borrowings" within "Liquidity and Capital Resources".~~2020 are achieved.

During ~~2016,~~2017 we also completed acquisitions ~~of businesses that complement~~related to our ~~OEM~~anesthesia and ~~Asia reportable operating segments. In addition, during 2016, we acquired the remaining 26% ownership interest in an Indian affiliate from the noncontrolling shareholders.~~respiratory product portfolios and distributor to direct sales conversions. The total fair value of the consideration related to these acquisitions was $80.1 million.

See Note 4 to the condensed consolidated financial statements included in this report for additional information.

Change in Reportable Segments

Following our acquisition of Vascular Solutions, we commenced an integration program under which we are combining Vascular Solutions' businesses with some of our legacy businesses. As a result, effective during the fourth quarter of 2017, we realigned our operating segments. The changes to the operating segments were also made to reflect the manner in which our chief operating decision maker assesses business performance and allocates resources. We now have the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, we will continue to present certain segments, which currently include our Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because they are not material. All prior comparative periods presented have been restated to reflect these ~~transactions was $22.8 million.~~changes.

~~Critical Accounting Estimates~~

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

In our Annual Report on Form 10-K for the year ended December 31, 2016, we provided disclosure regarding our critical accounting estimates, which are reflective of significant judgments and uncertainties, are important to the presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions and conditions.

Results of Operations

As used in this discussion, "new products" are products ~~that we~~for which commercial sales have ~~sold for~~commenced within the past 36 months, ~~or less,~~ and “existing products” are products ~~that we have sold~~ for which commercial sales commenced more than 36 ~~months.~~months ago. Discussion of results of operations items that reference the effect of one or more acquired businesses (except as noted below with respect to acquired distributors) generally reflects the impact of the acquisitions within the first 12 months following the date of the acquisition. In addition to increases and decreases in the per unit selling prices of our products to our customers, our discussion of the impact of product price increases and decreases also reflects, for the first 12 months following the acquisition or termination of a distributor, the impact on the pricing of our products resulting from the elimination of the distributor from the sales channel. To the extent an acquired distributor had pre-acquisition sales of products other than ours, the impact of the post-acquisition sales of those products on our results of operations is included within our discussion of the impact of acquired businesses.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Net Revenues

Three Months Ended
April 2, 2017 March 27, 2016
(Dollars in millions)
Net Revenues $ 487.9
$ 424.9



	Three Months Ended
	April 1, 2018		April 2, 2017
	(Dollars in millions)
Net Revenues	$	587.2	$	487.9

Net revenues for the three months ended April ~~2, 2017~~1, 2018 increased ~~$63.0~~$99.3 million, or ~~14.8%~~20.4%, compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to net revenues of ~~$24.2~~$65.6 million generated by ~~the~~ acquired businesses ~~mainly Vascular Solutions,~~ and ~~a $32.8~~the $24.5 million ~~increase~~impact of favorable fluctuations in ~~sales volume, primarily resulting from an increase in the number of shipping days during the 2017 period.~~foreign currency exchange rates.

Gross profit


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars in millions)						(Dollars in millions)
Gross profit	$	255.6		$	225.1		$	331.3		$	255.6
Percentage of sales	52.4		%	53.0		%	56.4		%	52.4		%

Gross margin for the three months ended April ~~2, 2017 declined 60~~1, 2018 increased 400 basis points, or ~~1.1%~~7.6%, compared to the ~~first quarter 2016.~~prior year period. The ~~decrease~~increase in gross margin ~~primarily~~ reflects the adverse impact to the prior year period of the step-up in carrying value of inventory recognized in connection with the Vascular ~~Solutions'~~Solutions acquisition, ~~that was sold during~~ the ~~first quarter 2017 partially offset by an increase in~~favorable impact of gross margin ~~on the business excluding~~generated by acquired businesses, mainly NeoTract and Vascular Solutions, ~~which reflects~~favorable fluctuations in foreign currency exchange rates and the favorable impact of ~~higher sales volumes.~~

cost improvement initiatives, including the 2016 and 2014 Footprint realignment restructuring plans.

Selling, general and administrative


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars in millions)						(Dollars in millions)
Selling, general and administrative	$	164.0		$	136.3		$	215.3		$	164.0
Percentage of sales	33.6		%	32.1		%	36.7		%	33.6		%

Selling, general and administrative expenses for the three months ended April ~~2, 2017~~1, 2018 increased ~~$27.7~~$51.3 million compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to ~~a $17.6~~$49.1 million ~~increase~~ in ~~costs associated with~~operating expenses incurred by acquired businesses, ~~including transaction fees~~primarily NeoTract, and ~~other related nonrecurring expenses resulting from the Vascular Solutions acquisition of $8.9 million, as well as~~ an increase in ~~selling~~contingent consideration expense of $9.4 million. These increases were partially offset by a $9.2 million decrease in transaction and ~~marketing expenses.~~other nonrecurring expenses; in 2017, we incurred transaction and other nonrecurring expenses in connection with several acquisitions, principally including Vascular Solutions.

Research and development


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars in millions)						(Dollars in millions)
Research and development	$	17.8		$	12.4		$	26.0		$	17.8
Percentage of sales	3.6		%	2.9		%	4.4		%	3.6		%

The increase in research and development ~~expense~~expenses for the three months ended April ~~2, 2017~~1, 2018 compared to the ~~first quarter 2016~~prior year period is primarily attributable to ~~increased spending on new~~expenses incurred in connection with our interventional and interventional urology product ~~development with respect to several of our segments and $2.5 million in expenses within our Vascular Solutions operating segment.~~portfolios.

Restructuring charges

Three Months Ended
April 2, 2017 March 27, 2016
(Dollars in millions)
Restructuring charges $ 12.9
$ 10.0



	Three Months Ended
	April 1, 2018		April 2, 2017
	(Dollars in millions)
Restructuring charges	$	3.1	$	12.9

For the three months ended April 1, 2018, we recorded $3.1 million in restructuring charges, which primarily related to termination benefits associated with the 2016 Footprint realignment plan.

For the three months ended April 2, 2017, we recorded $12.9 million in restructuring charges. The charges primarily related to termination benefits associated with the 2017 EMEA restructuring program and the 2017 Vascular Solutions integration program, both of which are described below, of $7.1 million and $4.5 million, respectively.

~~For the three months ended March 27, 2016, we recorded $10.0 million in restructuring~~ charges, which primarily related to termination benefits associated with the ~~2016 footprint~~EMEA restructuring program and the Vascular Solutions integration program.

2018 Footprint realignment ~~plan.~~plan

On May 1, 2018, we initiated a restructuring plan involving the relocation of certain manufacturing operations to an existing lower-cost location, the outsourcing of certain distribution operations and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to commence in the second quarter 2018 and are expected to be substantially completed by the end of 2024.

We estimate that we will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2018 Footprint realignment plan of $102 million to $133 million, of which, we expect $55 million to $72 million to be incurred in 2018 and most of the balance is expected to be incurred prior to the end of 2024. We estimate that $99 million to $127 million of these charges will result in future cash outlays, of which, $9 million to $10 million is expected to be made in 2018 and most of the balance is expected to be made by the end of 2024. Additionally, we expect to incur $19 million to $23 million in aggregate capital expenditures under the plan, of which up, to $1 million is expected to be incurred during 2018 and most of the balance is expected to be incurred by the end of 2021.

We expect to begin realizing plan-related savings in 2018 and expect to achieve annual pre-tax savings of $25 million to $30 million once the plan is fully implemented.

Anticipated charges and pre-tax savings related to restructuring programs and other similar cost savings initiatives

In addition to the ~~restructuring programs initiated during the first quarter 2017,~~2018 Footprint realignment plan, we have ~~other~~ ongoing restructuring programs related to (i) the integration of Vascular Solutions into Teleflex; (ii) the centralization of certain administrative functions in our EMEA segment; (iii) the consolidation of our manufacturing operations (referred to as our 2016 and 2014 ~~footprint~~Footprint realignment plans) ~~as well as~~; and (iv) other restructuring programs designed to improve operating efficiencies and reduce costs. See Note 45 to the condensed consolidated financial statements included in this report. We also have similar ongoing activities to relocate certain manufacturing operations within our OEM segment that do not meet the criteria for a qualified restructuring program ("the OEM initiative"), but the activities will result in cost savings (despite minimal costs expected to be incurred). With respect to our restructuring plans and programs and the ~~following~~OEM initiative, the table below summarizes (1) the estimated total ~~cost~~restructuring and restructuring related charges and estimated annual pre-tax savings (including pre-tax savings related to the OEM initiative) and synergies once the programs are completed; (2) the ~~costs~~restructuring

and restructuring related charges incurred and estimated pre-tax savings realized through December 31, ~~2016;~~2017; and (3) the ~~costs~~restructuring and restructuring related charges expected to be incurred and estimated incremental pre-tax savings (including pre-tax savings related to the OEM initiative) and synergies estimated to be realized for these programs from January 1, ~~2017~~2018 through the anticipated completion ~~dates:~~dates.

Estimated charges and pre-tax savings are subject to change based on, among other things, the nature and timing of restructuring and similar activities, changes in the scope of restructuring plans and programs and the OEM initiative, unanticipated expenditures and other developments, the effect of additional acquisitions or dispositions and other factors that were not reflected in the assumptions made by management in previously estimating restructuring and restructuring related charges and estimated pre-tax savings. Moreover, estimated pre-tax savings relating to programs involving the integration of acquired businesses are particularly difficult to forecast because the estimate of pre-tax savings, to a considerable extent, involves assumptions regarding operation of businesses during periods when those businesses were not administered by our management. It is likely that estimates of charges and pre-tax savings will change from time to time, and the table below reflects changes from amounts previously estimated. In addition, the table below has been updated to remove estimated charges and pre-tax savings related to completed programs. Estimated charges expected to be incurred in connection with the restructuring programs are described in more detail in Notes 5 and 16 to the condensed consolidated financial statements included in this report.



	Ongoing ~~Restructuring Plans~~restructuring programs and ~~Programs~~other similar cost savings initiatives₍₁₎
	Estimated Total	Through December 31, ~~2016~~2017	Estimated Remaining from January 1, ~~2017~~2018 through December 31, ~~2021~~₍₂₎2024
	(Dollars in millions)
Restructuring charges	$51106 - ~~$60~~$125	$3342	$1864 - ~~$27~~$83
Restructuring related charges ₍₁₎₍₂₎	5396 - 65127	3044	2352 - 3583
Total charges	$~~104~~202 - ~~$125~~	63$252	$4186	$116 - ~~$62~~$166

OEM initiative pre-tax savings	$6 - $7	$—	$6 - $7
Pre-tax savings₍₃₎₍₄₎	$60101 - ~~$71~~	31$120	$~~29 - $40~~
~~Vascular Solutions integration program - synergies~~	~~$20 - $25~~	—45	$2056 - ~~$25~~$75
Total pre-tax savings	$107 - $127	$45	$62 - $82

(1)

~~Restructuring related charges principally constitute accelerated depreciation and other costs primarily~~Includes estimated financial information related to the ~~transfer of manufacturing operations to new locations~~2018 Footprint realignment plan, which was initiated during the second quarter 2018 and ~~are expected to be recognized primarily~~is described in ~~cost of goods sold.~~more detail above.

(2)

~~We expect~~Restructuring related charges principally constitute pre-tax charges related to ~~incur substantially all of the~~accelerated depreciation and other costs ~~prior~~directly related to the ~~end of 2018,~~plan, primarily costs to transfer manufacturing operations to the new location and project management costs, as well as a charge associated with our exit from the facilities that is expected to ~~have realized substantially all of the estimated annual pre-tax savings and synergies~~be imposed by the ~~year ended December 31, 2019.~~taxing authority in the affected jurisdiction. Most of these charges (other than the tax charge) are expected to be recognized in costs of goods sold

(3)

Approximately 65% of the pre-tax savings isare expected to result in reductions to cost of goods sold. ~~During~~As previously disclosed, during 2016, in connection with our execution of the 2014 ~~footprint~~Footprint realignment plan, we implemented changes to medication delivery devices included in certain of our kits, which are expected to result in increased product costs (and therefore ~~reduce~~reduced the annual savings ~~that were estimated~~we anticipated at the inception of the program). However, we also expect to achieve improved pricing on these kits to offset the cost, which is expected to result in estimated annual increased revenues of $5 million to $6 ~~million.~~million, which is not reflected in the table above. We ~~expect to begin realizing the benefits of~~realized a $1.0 million benefit resulting from this incremental pricing in 2017. ~~Savings generated from restructuring programs are difficult~~Moreover, during the fourth quarter of 2017, we entered into an agreement with an alternate provider for the development and supply of a component to ~~estimate, given~~be included in certain kits sold by our Vascular and Anesthesia North America operating segments. The agreement will result in increased development costs, but is expected to reduce the ~~nature and timing~~cost of the ~~restructuring activities and~~component supply, once the ~~possibility that unanticipated expenditures may~~supply becomes commercially available, as compared to the costs incurred with respect to our current suppliers. Therefore, we anticipate a net savings from the agreement, which is reflected in the table above.

(4)

While pre-tax savings address anticipated cost savings to be ~~required as the program progresses. Moreover, predictions of revenues related~~realized with respect to our historical expense items, they also reflect anticipated efficiencies to be realized with respect to increased ~~pricing~~costs that otherwise would have resulted from our acquisition of Vascular Solutions and Pyng Medical Corp. ("Pyng"), which we acquired in 2017. In this regard, the pre-tax savings are ~~particularly uncertain~~expected to result from the elimination of redundancies between our operations and ~~can be affected by a number~~Vascular Solutions’ and Pyng's operations, principally through the elimination of ~~factors, including customer resistance to price increases and competition.~~personnel redundancies.

~~The following provides additional details with respect to our programs initiated in 2017:~~

~~2017 Vascular Solutions Integration Program~~

During the first quarter 2017, we committed to a restructuring program related to the integration of Vascular Solutions' operations with our operations. We initiated the program in the first quarter 2017 and expect the program to be substantially completed by the end of the second quarter 2018. We estimate that we will record aggregate pre-tax restructuring charges of $6.0 million to $7.5 million related to this program, of which $4.5 million to $5.3 million will constitute termination benefits, and $1.5 million to $2.2 million will relate to other exit costs, including employee relocation and outplacement costs. Additionally, we expect to incur $2.5 million to $3.0 million of restructuring related charges consisting primarily of retention bonuses offered to certain employees expected to remain with the Company after completion of the program. All of these charges will result in future cash outlays. We began realizing program-related synergies in the first quarter 2017 and expect to achieve annualized pre-tax synergies of $20 million to $25 million once the program is fully implemented.

~~2017 EMEA Restructuring Program~~

During the first quarter 2017, we committed to a restructuring program to centralize certain administrative functions in Europe. The program will commence in the second quarter 2017 and is expected to be substantially completed by the end of 2018. We estimate that we will record aggregate pre-tax restructuring charges of $7.1 million to $8.5 million related to this program, almost all of which constitute termination benefits, and all of which will result in future cash outlays. We expect to achieve annualized pre-tax savings of $2.7 million to $3.3 million once the program is fully implemented and expect to begin realizing plan related savings in the first quarter 2018.

Interest expense


	Three Months Ended						Three Months Ended
	April 2, 2017			March 27, 2016			April 1, 2018			April 2, 2017
	(Dollars in millions)						(Dollars in millions)
Interest expense	$	17.7		$	13.8		$	25.9		$	17.7
Average interest rate on debt	3.5		%	3.5		%	4.2		%	3.5		%

The increase in interest expense for the three months ended April ~~2, 2017~~1, 2018 compared to the ~~first quarter 2016~~prior year period was primarily due to an increase in average debt outstanding ~~mainly~~resulting from additional borrowings under our principal credit facility, as well as the ~~Credit Agreement that were utilized to fund the Vascular Solutions acquisition,~~November 2017 issuance of our 4.625% Senior Notes due 2027 ("2027 Notes"). The increase in ~~addition to~~ interest expense was also the result of ~~$2.1 million incurred in connection with~~ a bridge facility (the "Bridge Facility") and backstop commitment (the "Backstop Commitment") related to our entry into the agreement and plan of merger under which we ultimately acquired Vascular Solutions. The Bridge Facility and Backstop Commitment were put in placehigher average interest rate on December 1, 2016 to, among other things, enable us to finance the acquisition of Vascular Solutions. The Bridge Facility and Backstop Commitment were not utilized, as the required financing was provided under the Credit Agreement, which amended and restated the agreement relating to our then-existing credit facility.debt.

Loss on extinguishment of debt

Three Months Ended
April 2, 2017 March 27, 2016
(Dollars in millions)
Loss on extinguishment of debt $ 5.6
$ —



	Three Months Ended
	April 1, 2018		April 2, 2017
	(Dollars in millions)
Loss on extinguishment of debt	$	—	$	5.6

For the three months ended April 2, 2017, ~~we recognized a~~the loss on the extinguishment of debt ~~of $5.6 million, of which $5.2 million~~was primarily related to our repurchase of ~~Convertible Notes~~convertible notes through exchange transactions we entered into with certain holders of the ~~Convertible Notes and $0.4 million related to the amendment and restatement of our previous credit agreement, which was considered a partial extinguishment of debt.~~convertible notes.

Taxes on income from continuing operations

Three Months Ended
April 2, 2017 March 27, 2016
Effective income tax rate (7.1 )% 4.9 %



	Three Months Ended
	April 1, 2018		April 2, 2017
Effective income tax rate	10.2	%	(7.1	)%

In accordance with the applicable provisions of SEC Staff Accounting Bulletin No. 118 ("SAB 118"), the Company included in its consolidated financial statements as of December 31, 2017 provisional amounts reflecting the tax impact related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities. Once our accounting for the income tax effects of the TCJA is complete, the amounts with respect to the income tax effects of the TCJA may differ from the provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions we have made, additional regulatory guidance that may be issued, and actions we may take as a result of the TCJA.

The effective income tax rate for the three months ended April 1, 2018 and April 2, 2017 was 10.2% and ~~March 27, 2016 was~~ (7.1)% ~~and 4.9%~~, respectively. The effective income tax rate for the three months ended April ~~2, 2017, as compared to~~1, 2018 includes the ~~first quarter 2016, reflects an excess~~benefit of a lower U.S. corporate income tax ~~benefit~~rate of 21.0% from the enactment of the TCJA, partially offset by a tax cost associated with share based payments, recognized under the new FASB guidance adopted by the Company as of January 1, 2017. In addition, the Company recognized discrete tax benefits associated the acquisition of Vascular Solutions.GILTI and other TCJA related changes. The effective income tax rate for the three months ended ~~March 27, 2016~~April 2, 2017 reflects a tax benefit onassociated with costs incurred in connection with the ~~settlement of a foreign tax audit.~~Vascular Solutions acquisition.

Segment Financial Information


	Three Months Ended							Three Months Ended
	April 2, 2017			March 27, 2016		% Increase/ (Decrease)		April 1, 2018			April 2, 2017			% Increase/ (Decrease)
Segment Revenue	(Dollars in millions)
								(Dollars in millions)
Vascular North America	$	93.8		$	81.5	15.0		$	83.0		$	79.0		5.1
Interventional North America								60.2			39.9			50.7
Anesthesia North America	48.2			46.0		4.9		50.6			48.2			4.9
Surgical North America	46.0			38.9		18.0		40.7			46.0			(11.5	)
EMEA	130.7			122.1		7.1		159.9			133.6			19.7
Asia	49.0			49.2		(0.4	)	58.2			50.2			16.1
OEM	43.3			34.0		27.6		45.8			43.3			5.8
All other	76.9			53.2		44.5		88.8			47.7			86.2
Segment net revenues	$	487.9		$	424.9	14.8
Net revenues								$	587.2		$	487.9		20.4

	Three Months Ended							Three Months Ended
	April 2, 2017			March 27, 2016		% Increase/ (Decrease)		April 1, 2018			April 2, 2017			% Increase/ (Decrease)
Segment Operating Profit	(Dollars in millions)
								(Dollars in millions)
Vascular North America	$	24.8		$	19.7	26.3		$	24.7		$	18.3		34.8
Interventional North America								14.1			(8.0		)	275.7
Anesthesia North America	13.5			12.2		11.1		17.3			13.3			30.3
Surgical North America	16.4			13.3		23.6		14.7			16.4			(10.0	)
EMEA	22.3			21.0		5.7		31.8			21.3			49.1
Asia	10.8			13.0		(17.0	)	13.4			10.9			22.8
OEM	9.1			5.2		75.8		9.0			9.1			(1.2	)
All other	(6.3		)	5.7		(209.7	)	(12.0		)	9.3			(228.4	)
Segment operating profit ⁽¹⁾	$	90.6		$	90.1	0.6		$	113.0		$	90.6		24.8


(1)	See Note 14 to our condensed consolidated financial statements included in this report for a reconciliation of segment operating profit to our condensed consolidated income from continuing operations before interest, loss on extinguishment of debt and taxes.

Comparison of the three months ended April 1, 2018 and April 2, 2017 ~~and March 27, 2016~~

Vascular North America

Vascular North America net revenues for the three months ended April ~~2, 2017~~1, 2018 increased ~~$12.3~~$4.0 million, or ~~15.0%~~5.1% compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to a ~~$9.0~~$1.6 million increase in new product sales and a $1.5 million increase in sales ~~volume, including the impact~~volumes of ~~an increase in the number of~~existing products despite one less shipping ~~days~~day in the first quarter ~~2017.~~2018 as compared to the comparable prior year period.

Vascular North America operating profit for the three months ended April ~~2, 2017~~1, 2018 increased ~~$5.1~~$6.4 million, or ~~26.3%~~34.8%, compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to an increase in gross profit resulting from anlower manufacturing costs as well as the impact of increases in sales volumes, prices and new product sales. The increase in ~~sales volume, partially offset~~operating profit also reflects lower selling, general and administrative expenses.

Interventional North America

Interventional North America net revenues for the three months ended April 1, 2018 increased 20.3 million , or 50.7% compared to the prior year period. The increase is primarily attributable to net revenues generated by ~~higher~~Vascular Solutions of $18.7 million and to a lesser extent, new products.

Interventional North America operating ~~expenses.~~profit for the three months ended April 1, 2018 increased 22.1 million, or 275.7% compared to the prior year period. The increase is primarily attributable to operating profit generated by Vascular Solutions. The prior year period was adversely affected by transaction and other expenses as well as the step-up in carrying value of inventory recognized in connection with the Vascular Solutions acquisition.

Anesthesia North America

Anesthesia North America net revenues for the three months ended April ~~2, 2017~~1, 2018 increased ~~$2.2~~$2.4 million, or 4.9%, compared to the first quarter 2016. The increase is primarily attributable to a $4.0 million increase in sales volumes resulting from the impact of an increase in the number of shipping days in the first quarter 2017 as well as new product sales and price increases.prior year period. The increase in net revenues ~~was partially offset by a $3.3 million decrease in sales volumes of existing products excluding the impact of~~is primarily attributable to an increase in ~~the number~~new product sales of ~~shipping days in the first quarter 2017.~~$1.3 million and net revenues generated by an acquired business.

Anesthesia North America operating profit for the three months ended April ~~2, 2017~~ 1, 2018increased ~~$1.3~~$4.0 million, or ~~11.1%,~~30.3% compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to an increase in gross profit ~~reflecting~~resulting from a more favorable product mix as well as lower ~~manufacturing costs~~selling, general and ~~the impact of favorable fluctuations in foreign currency exchange rates partially offset by a decrease in sales of higher margin products, and an increase in research and development~~administrative expenses.

Surgical North America

Surgical North America net revenues for the three months ended April ~~2, 2017 increased $7.1~~1, 2018 decreased $5.3 million, or ~~18.0%~~11.5%, compared to the ~~first quarter 2016. The increase is~~prior year period, primarily ~~attributable~~due to a ~~$3.9~~$6.3 million ~~increase~~decrease in sales ~~volume, including the impact~~volumes of ~~an increase in the number of shipping days in the first quarter 2017, and an increase in new product sales of $2.4 million.~~existing products.

Surgical North America operating profit for the three months ended April ~~2, 2017 increased $3.1~~1, 2018 decreased $1.7 million, or ~~23.6%~~10.0%, compared to the ~~first quarter 2016. The increase~~prior year period, which is primarily attributable ~~to an increase~~a decrease in gross profit ~~due to an increase in~~resulting from lower sales ~~volume and new product sales,~~volumes partially offset by ~~higher~~lower selling, general and administrative expenses.

EMEA

EMEA net revenues for the three months ended April ~~2, 2017~~1, 2018 increased ~~$8.6~~$26.3 million, or ~~7.1%~~19.7%, compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to ~~an $11.2 million increase in sales volume, including the impact of an increase in the number of shipping days in the first quarter 2017, partially offset by unfavorable~~favorable fluctuations in foreign currency exchange rates of ~~$4.2 million.~~$19.3 million and, to a lesser extent, net revenues generated by acquired businesses and price increases.

EMEA operating profit for the three months ended April ~~2, 2017~~1, 2018 increased ~~$1.3~~$10.5 million, or ~~5.7%~~49.1%, compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to an increase in gross profit ~~largely resulting from the increase in sales volume partially offset by~~reflecting the impact of ~~unfavorable~~favorable fluctuations in foreign currency exchange ~~rates. The increase in operating profit was~~rates and the impact of the Vascular Solutions acquisition and subsequent distributor to direct sales conversions with respect to the Vascular Solutions business. These increases were partially offset by higher ~~selling, general~~amortization and ~~administrative~~selling expenses.

Asia

Asia net revenues for the three months ended April ~~2, 2017 decreased $0.2~~1, 2018 increased $8.0 million, or ~~0.4%~~16.1%, compared to the ~~first quarter 2016.~~prior year period. The ~~decrease was~~increase is primarily attributable to ~~a $1.6~~favorable fluctuations in foreign currency exchange rates of $3.2 million, ~~decrease~~an increase in sales volumes ~~including~~of existing products of $2.6 million as well as net revenues generated by the impact of a distributor to direct sales conversion in China, partially offset by an increase in new product sales and price increases. As previously disclosed, we expect to continue to experience a decline in sales and operating profit in our Asia segment during 2017 as our former distributor liquidates its inventory of our products and we implement our new structure to support these sales. However, the distributor recently commenced an arbitration proceeding against us, seeking, among other things, to compel our repurchase of Teleflex products that the distributor alleges are currently held in its inventory. See Note 13 to the condensed consolidated financial statements included in this report for additional information.acquired businesses.

Asia operating profit for the three months ended April ~~2, 2017 decreased $2.2~~1, 2018 increased $2.5 million, or ~~17.0%~~22.8%, compared to the ~~first quarter 2016.~~prior year period. The ~~decrease is~~increase was primarily attributable to an increase in ~~selling expenses, as well as a decrease in~~ gross profit ~~resulting from~~reflecting the impact of ~~unfavorable~~favorable fluctuations in foreign currency exchange rates ~~lower~~and an increase in sales volumes ~~and a decrease in sales~~ of existing products. These increases were partially offset by higher ~~margin products.~~operating expenses.

OEM

OEM net revenues for the three months ended April ~~2, 2017~~1, 2018 increased ~~$9.3~~$2.5 million, or ~~27.6%~~5.8%, compared to the ~~first quarter 2016.~~prior year period. The increase is primarily attributable to ~~a $7.3 million~~an increase in sales ~~volume~~volumes of existing products of $1.5 million and ~~net revenues generated by acquired businesses~~favorable fluctuations in foreign currency exchange rates of ~~$2.6~~$1.2 million.

OEM operating profit for the three months ended April ~~2, 2017 increased $3.9~~1, 2018 decreased $0.1 million, or ~~75.8%~~1.2%, compared to the ~~first quarter 2016.~~prior year period. The ~~increase~~decrease is primarily attributable to ~~an increase in gross profit due to the increase in sales volume, which also had a favorable impact on~~higher manufacturing costs ~~and profit generated by the acquired businesses. The increases in operating profit were~~ partially offset by ~~an increase in general and administrative expenses as well as research and development expenses.~~the impact of higher sales volumes.

All Other

Net revenues for our other operating segments increased ~~$23.7~~$41.1 million, or ~~44.5%~~86.2%, ~~for the three months ended April 2, 2017~~ compared to the ~~first quarter 2016.~~prior year periods. The increase is primarily attributable to net revenues ~~of $21.6 million~~ generated by ~~sales of Vascular Solutions' products.~~NeoTract.

Operating profit for our other operating segments ~~decreased $12.0 million or 209.7%~~ for the three months ended April ~~2, 2017,~~1, 2018 decreased $21.3 million, or 228.4%, compared to the ~~first quarter 2016.~~prior year period. The decrease is primarily attributable to ~~higher~~ operating expenses ~~resulting from the Vascular Solutions acquisition, including transaction fees and related expenses, which were partially offset by an increase in gross profit.~~associated with NeoTract.

Liquidity and Capital Resources

We believe our cash flow from operations, available cash and cash equivalents, and borrowings under our revolving credit facility ~~and our accounts receivable securitization facilities~~ will enable us to fund our operating requirements, capital expenditures and debt obligations for the next 12 months and the foreseeable future. We have net cash provided by United States based operating activities as well as non-United States sources of cash available to help fund our debt service requirements in the United States. We manage our worldwide cash requirements by monitoring the funds available among our subsidiaries and determining the extent to which we can access those funds on a cost effective basis.

The TCJA significantly changes U.S. tax law by, among other things, imposing a one-time repatriation tax on undistributed post-1986 earnings and profits of foreign subsidiaries. Previously, we were not taxed in the U.S. on certain foreign earnings unless and until they were repatriated to the U.S. Under the TCJA, we will have to pay $154.0 million over eight years for the deemed repatriation of these foreign earnings, regardless of whether such earnings are actually repatriated. As a result of the repatriation tax provisions of the TCJA, we anticipate that, generally, we will be able to access cash located at our foreign subsidiaries without incurring any additional U.S. federal income tax liabilities. We are not aware of any other restrictions on repatriation of these funds and, subject to cash payment of additional ~~United States income taxes or~~ foreign withholding taxes, these funds could be repatriated, if necessary. Any resulting additional taxes could be offset, at least in part, by foreign tax credits. The amount of any taxes required to be paid, which could be significant, and the application of tax credits would be determined based on income tax laws in effect at the time of such repatriation. We do not expect any such repatriation to result in additional tax expense because taxes have been provided for on unremitted foreign earnings that we do not consider permanently reinvested.

To date, we have not experienced significant payment defaults by our customers, and we have sufficient lending commitments in place to enable us to fund our anticipated additional operating needs. However, although there have been recent improvements in certain countries, global financial markets remain volatile and the global credit markets are constrained, which creates a risk that our customers and suppliers may be unable to access liquidity. Consequently, we continue to monitor our credit risk, particularly with respect to customers in Greece, Italy, Portugal and Spain, and consider other mitigation strategies. As of April ~~2, 2017~~1, 2018 and December 31, ~~2016,~~2017, our net trade accounts receivable from publicly funded hospitals in Italy, Spain, Portugal and Greece were ~~$22.9~~$29.4 million and ~~$29.2~~$24.7 million, respectively. As of April ~~2, 2017~~1, 2018 and December 31, ~~2016,~~2017, our net trade accounts receivable from customers in these countries were approximately ~~16.4%~~16.3% and ~~19.3%~~15.0%, respectively of our consolidated net trade accounts receivable. For the three months ended April 1, 2018 and April 2, 2017, ~~and March 27, 2016,~~ net revenues from customers in these countries were 6.5% ~~and 7.3%~~ of total net revenues, ~~respectively,~~ and average days that current and long-term trade accounts ~~receivables~~receivable were outstanding were ~~155~~152 days and ~~215~~155 days, respectively. If economic conditions in these countries deteriorate, we may experience significant credit losses related to the public hospital systems in these countries. Moreover, if global economic conditions generally deteriorate, we may experience further delays in customer payments, reductions in our customers’ purchases and higher credit losses, which could have a material adverse effect on our results of operations and cash flows in ~~2017~~2018 and future years. ~~In January 2017, we sold $16.1 million of receivables payable from publicly funded hospitals in Italy for $16.0 million.~~

Cash Flows

Cash flows from operating activities from continuing operations provided net cash of approximately $86.8 million for the three months ended April 1, 2018 as compared to $90.9 million for the three months ended April 2, ~~2017 as compared to $66.8~~2017. The $4.1 million ~~for the three months ended March 27, 2016. The $24.1 million increase~~decrease is attributable to a net ~~favorable~~unfavorable impact from changes in working capital ~~and favorable operating results despite transaction costs and related expenses incurred in connection with the Vascular Solutions acquisition of $8.9 million,~~ partially offset by favorable operating results. The net unfavorable impact from changes in working capital were the result of a net decrease in accounts payable and accrued expenses and a net increase in accounts receivable partially offset by a net increase in income taxes payable, net.

The decrease in accounts payable and other accrued expenses for the three months ended April 1, 2018 was $27.2 million compared to an increase of $2.7 million for three months ended April 2, 2017. The decrease is attributable to higher restructuring activity and payroll and benefit related payments. The increase in accounts receivable for the ~~cash outflow~~three months ended April 1, 2018 was $3.4 million compared to a decrease of $18.7 million for ~~income taxes~~three months ended April 2, 2017. The net increase in accounts receivable ~~payable,~~is attributable to the sale of receivables outstanding with public hospitals in Italy for $16.0 million during the first quarter 2017 as well as higher net ~~resulting from fewer refunds~~revenues in the first quarter ~~2017~~2018. The increase in incomes taxes payable, net was the result of lower payments in the first quarter 2018 as compared to the first quarter 2016. The increase in net cash inflow from working capital is primarily the result of an increase in cash inflows for accounts receivable. The cash inflow for accounts receivable was $18.7 million for the three months ended April 2, 2017 as compared to an outflow of $10.6 million for the three months ended March 27, 2016. The increase is attributable to improved collections as well as the sale of receivables outstanding with publicly funded hospitals in Italy for $16.0 million.2017.

Net cash used in investing activities from continuing operations was ~~$982.1~~$19.4 million for the three months ended April ~~2, 2017, primarily resulting from the payment~~1, 2018, which includes a cash outflow for ~~the Vascular Solutions acquisition of $975.5 million,~~ capital expenditures of ~~$12.9~~$15.7 million ~~which were partially offset by proceeds~~and acquisition payments of ~~$6.3~~$3.7 million ~~from the sale of two properties, one of which had been classified as a held for sale building asset.~~principally related to distributor to direct sales conversions.

Net cash used in financing activities from continuing operations was ~~$1,021.3~~$32.7 million for the three months ended April ~~2, 2017, primarily resulting from a net increase in~~1, 2018, which includes an $18.5 million repayment of borrowings of $1,056.2 million. There was an increase in borrowings under the Credit Agreement, which was utilized to finance the Vascular Solutions acquisition, partially offset by a reduction in borrowings under the Convertible Notes resulting from the Exchange Transactions. Net cash used in financing activities from continuing operation was also impacted byand dividend payments of $15.3 million and debt issuance and amendment fees of $19.1 million, which included fees paid in connection with the signing of the Credit Agreement and a Bridge Facility and Backstop Commitment, which was also put in place to assist with the financing

~~of the Vascular Solutions acquisition, but never utilized as the required financing was provided under the Credit Agreement~~ .15.4 million.

Borrowings

~~Our 3.875% Convertible Senior Subordinated Notes due 2017 (the "Convertible Notes") are convertible under certain circumstances, as described in Note 8~~

The credit agreement relating to ~~the consolidated financial statements included in~~ our ~~annual report on Form 10-K for the year ended December 31, 2016. Since the fourth quarter 2013, our closing stock price has exceeded the threshold for conversion. Moreover, commencing on May 1, 2017~~revolving credit facility and ~~through July 28, 2017, the Convertible Notes are convertible regardless of the closing price of our stock. Accordingly, the Convertible Notes were classified as~~ a ~~current liability as of April 2, 2017 and December 31, 2016. We have elected~~term loan used to fund a net settlement method to satisfy our conversion obligations, under which we settle the principal amount of the Convertible Notes in cash and settle the excess of the conversion value of the Convertible Notes over the principal amount of the notes in shares; however, cash will be paid in lieu of fractional shares. The Convertible Notes will mature in August 2017.

In January 2017, we acquired $91.7 million aggregate outstanding principal amount of the Convertible Notes in exchange for an aggregate of $93.2 million in cash (including approximately $1.5 million in accrued and previously unpaid interest) and approximately 0.93 million shares of our common stock (the “Exchange Transactions”). We funded the cash portion of the consideration we paid ~~through borrowings under our revolving credit facility. While we believe we have sufficient liquidity~~ to repay the remaining 44.3 million outstanding principal amount of the Convertible Notes through a combination of our existing cash on hand and borrowings under our credit facility, our use of these funds could adversely affect our results of operations and liquidity.

On January 20, 2017, we entered into the Credit Agreement, which provides for a five-year revolving credit facility of $1.0 billion and a term loan facility of $750.0 million. The availability of loans under our revolving credit facility is dependent upon our ability to maintain continued compliance with the financial and other covenants contained in the Credit Agreement. Moreover, additional borrowings would be prohibited if an event resulting in a Material Adverse Effect (as defined in the Credit Agreement) were to occur. Notwithstanding these restrictions, we believe our revolving credit facility provides us with significant flexibility to meet our foreseeable working capital needs.

~~The Credit Agreement~~acquire Vascular Solutions (the “Credit Agreement”) and the indentures under which we issued our 5.25% Senior Notes due 2024 (the “2024 Notes”) and 4.875% Senior Notes due 2026 ~~Notes~~(the "2026 Notes") contain covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to incur additional debt or issue preferred stock or other disqualified stock; create liens; pay dividends, make investments or make other restricted payments; sell assets; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; or enter into transactions with our affiliates. The indenture with respect to our 2027 Notes contains covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to create liens; consolidate, merge or dispose of certain assets; and enter into sale leaseback transactions. Additionally, the Credit Agreement ~~also requires~~contains financial covenants that require us to maintain a consolidated total leverage ratio (generally, ~~the ratio of~~ Consolidated Total Funded Indebtedness, ~~to Consolidated EBITDA, each~~ as defined in the Credit ~~Agreement)~~Agreement, on the date of determination to Consolidated EBITDA, as defined in the Credit Agreement, for the four most recent fiscal quarters ending on or preceding the date of determination) of not more than 4.50 to 1.00, and a ~~maximum~~consolidated senior secured leverage ratio (generally, ~~consolidated senior secured funded indebtedness~~Consolidated Senior Secured Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to ~~adjusted consolidated~~Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination) of not more than 3.50 to 1.00. The Company is further required to maintain a consolidated interest coverage ratio (generally, ~~consolidated adjusted~~Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination to ~~consolidated interest expense~~Consolidated Interest Expense, as defined in the Credit Agreement, paid in cash for such period) of not less than 3.50 to 1.00.

As of April ~~2, 2017,~~1, 2018, we were in compliance with these ~~covenants.~~requirements. The obligations under the Credit Agreement, the 2024 Notes, the 2026 Notes and the ~~2026~~2027 Notes are guaranteed (subject to certain exceptions) by substantially all of our material domestic subsidiaries, and the obligations under the Credit Agreement are (subject to certain exceptions and limitations) secured by a lien on substantially all of the assets owned by us and each guarantor.

~~See Note 7 to the condensed~~Critical Accounting Estimates

The preparation of consolidated financial statements ~~included~~ in ~~this report for additional information regarding~~conformity with GAAP requires management to make estimates and assumptions that affect the ~~Exchange Transactions~~reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the ~~Credit Agreement.~~

~~Contractual obligations~~

~~The following table sets forth our contractual obligations related to our total borrowings~~reported amounts of revenues and ~~interest as of April 2, 2017 (in thousands), which, as a result of the signing of the Credit Agreement~~expenses during the ~~first quarter 2017, has significantly change since~~reporting period. Actual results could differ from those estimates and assumptions.

In our Annual Report on Form 10-K for the year ended December 31, ~~2016:~~2017, we provided disclosure regarding our critical accounting estimates, which are reflective of significant judgments and uncertainties, are important to the presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions and conditions.

Payments due by period
Total Less than
1 year 1-3
years 3-5
years More than
5 years
(Dollars in thousands)
Total borrowings $ 2,012,325
$ 131,825
$ 75,000
$ 1,245,500
$ 650,000
Interest obligations⁽¹⁾
429,904
67,588
130,849
121,233
110,234


~~(1)~~	~~Interest payments on floating rate debt are based on the interest rate in effect on April 2, 2017.~~

New Accounting Standards

See Note 2 to the condensed consolidated financial statements included in this report for a discussion of recently issued accounting standards, including estimated effects, if any, on our financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

See the information set forth in Part II, Item 7A of the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is

(i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management’s assessment of disclosure controls and procedures excluded consideration of ~~Vascular Solutions’~~NeoTract’s internal control over financial reporting. ~~Vascular Solutions~~NeoTract was acquired during the ~~first~~fourth quarter of 2017 and the exclusion is consistent with guidance provided by the staff of the Securities and Exchange Commission that an assessment of a recently acquired business may be omitted from management’s report on internal control over financial reporting for up to one year from the date of acquisition, subject to specified conditions. ~~Vascular Solutions’~~NeoTract's total assets (excluding goodwill and intangible assets) were ~~approximately $1.2 billion~~$49.5 million as of April ~~2, 2017;~~1, 2018; its revenues ~~during~~for the three months ended April ~~2, 2017~~1, 2018 were ~~approximately $21.6~~$42.3 million.

(b) Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. As a result of our acquisition of Vascular Solutions, we are in the process of evaluating Vascular Solutions’ internal controls to determine the extent to which modifications to Vascular Solutions internal controls would be appropriate.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, commercial disputes, intellectual property, contracts, employment and environmental matters. As of April ~~2, 2017~~1, 2018 and December 31, ~~2016,~~2017, we have accrued liabilities of approximately ~~$2.4~~$1.8 million and $2.5 million, respectively, in connection with these matters, representing our best estimate of the cost within the range of estimated possible loss that will be incurred to resolve these matters. ~~Of the $2.4 million accrued at April 2, 2017, $1.7 million pertains to discontinued operations.~~ Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. See “Litigation” within Note 13 to the condensed consolidated financial statements included in this report for additional information.

Item 1A. Risk Factors

There have been no significant changes in risk factors for the quarter ended April ~~2, 2017.~~1, 2018. See the information set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

The following exhibits are filed as part of this report:



Exhibit No.		Description
10.1	—	~~Consulting Agreement,~~ Fifth Amendment to the Teleflex Incorporated 401(k) Savings Plan, dated March ~~31, 2017, between the Company and Benson F. Smith.~~
~~10.2~~	—	~~Senior Executive Officer Severance Agreement, dated March 31, 2017, between the Company and Liam Kelly.~~
~~10.3~~	—	~~Executive Change In Control Agreement, dated March 31, 2017, between the Company and Liam Kelly.~~28, 2018.
31.1	—	Certification of Chief Executive Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
31.2	—	Certification of Chief Financial Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
32.1	—	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	—	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1	—	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended April ~~2, 2017,~~1, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income for the three months ended April 1, 2018 and April 2, ~~2017 and March 27, 2016;~~2017; (ii) the Condensed Consolidated Statements of Comprehensive Income for the three months ended April 1, 2018 and April 2, ~~2017 and March 27, 2016;~~2017; (iii) the Condensed Consolidated Balance Sheets as of April ~~2, 2017~~1, 2018 and December 31, ~~2016;~~2017; (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended April ~~2, 2017~~1, 2018 and ~~March 27, 2016;~~April 25, 2017; (v) the Condensed Consolidated Statements of Changes in Equity for the three months ended April 1, 2018 and April 2, ~~2017 and March 27, 2016;~~2017; and (vi) Notes to Condensed Consolidated Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



		TELEFLEX INCORPORATED

		By:		/s/ ~~Benson F. Smith~~Liam J. Kelly
				~~Benson F. Smith~~Liam J. Kelly ~~Chairman~~President and Chief Executive Officer (Principal Executive Officer)

		By:		/s/ Thomas E. Powell
				Thomas E. Powell Executive Vice President and Chief Financial Officer (Principal Financial ~~and Accounting~~ Officer)

Dated: May ~~4, 2017~~3, 2018

4442



	Fair value	Useful life range
	(Dollars in thousands)	(Years)
Intellectual property	248,200	10- 20
In-process research and development ("IPR&D")	15,600	Indefinite
Trade names	16,650	20
Customer lists	258,800	25



	After Tax Gain (Loss) Recognized in OCI
	Three Months Ended
	April 2, 2017		March 27, 2016
	(Dollars in thousands)
Foreign currency forward contracts	$	1,728	$	1,480



	Contingent consideration
	2017
	(Dollars in thousands)
Balance - December 31, 2016	$	7,102
Payment	(79		)
Revaluations	179
Balance - April 2, 2017	$	7,202



			Payments due by period
	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
			(Dollars in thousands)
Total borrowings	$	2,012,325	$	131,825	$	75,000	$	1,245,500	$	650,000
Interest obligations⁽¹⁾	429,904		67,588		130,849		121,233		110,234

Valuation Technique

Unobservable Input

Contingent consideration

Monte Carlo simulation

Revenue volatility

Risk free rate

Cost of debt structure

Projected year of payment